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Various subtypes of nicotinic acetylcholine receptors (nAChRs) mediate 
ionotropic actions of acetylcholine in the central and peripheral nervous 
system. Due to the lack of highly selective nicotinic ligands, the precise 
location, functional roles and various disorders associated with nAChRs 
remain unclear. Neurotoxins isolated from snake venom have a natural high 
affinity and selectivity to nAChRs, which act as competitive antagonists of 
nAChRs. These neurotoxins may therefore be invaluable tools in studying 
nAChR physiology.  
The structure-function relationships of the classical neurotoxins, named α-
neurotoxins, which belong to three-finger toxin (3FTx) family of snake venom 
neurotoxins are competitive antagonists with nano-molar affinity and high 
selectivity towards nAChRs. In addition, the functional site of about 15 
residues involved in their interaction with nAChRs has been identified.  
This thesis reports the characterization of a new group of competitive 
antagonists of nAChRs, Ω-neurotoxins. Although they belong to 3FTx family, 
the conserved functional residues of α-neurotoxins are completely replaced in 
this group. Thus, they interact with nAChRs through a distinct set of residues 
compared to α-neurotoxins. As a typical example, I have evaluated the subtype 
specificity and structure-function relationships of Oh9-1 from Ophiophagus 




neurotoxicity in micromolar range. Experiments with different nAChR 
subtypes expressed in Xenopus oocytes indicated, Oh9-1 is selective for rat 
muscle-type α1β1εδ (adult), α1β1γδ (fetal) and rat neuronal α3β2 subtypes. 
However, it showed low or no affinity for other human and rat neuronal 
subtypes. Twelve individual alanine-scan mutants encompassing all three 
loops of Oh9-1 were evaluated for binding to α1β1εδ and α3β2 subtypes. 
Although loop-II residues were more critical for interactions and form the 
common binding core (M25, F27) mutations at T23 and F26 showed 
significant loss in the activity with α1β1εδ but had no effect in interaction with 
α3β2. Similarly, mutations at loops-II (H7, K22, H30) and -III (K45) of Oh9-1 
had distinctly different impacts on its blocking activity of these subtypes. 
Thus, Oh9-1 interacts with these nAChRs with distinct set of residues. Unlike 
α-neurotoxins, the tip of loop-II did not participate on both nAChRs. In 
addition a novel mode of interaction was revealed where Oh9-1 utilises both 
the sides of the β-strand of its loop-II to interact with α1β1εδ but only one side 
with α3β2. The interaction of Oh9-1 with acetylcholine binding protein 
(AChBP) using radioligand binding assays was observed with an ultimate aim 
of cocrystallization with this nAChR homolog. Oh9-1 did not compete with 
the radioligand to interact with AChBP. X-ray crystallography was employed 
to determine the three-dimensional structure of Oh9-1. The initial crystals 
obtained, are being further optimized to yield diffraction quality crystals for 
structural characterization of Oh9-1. 
 I also evaluated the subtype specificity of Exactin, a paralogue of Oh9-1, 




(VM Girish, PhD thesis, National University of Singapore, 2012). Despite 
sharing identical tip-region of loop-II with Oh9-1, Exactin exhibited distinct 
subtype selectivity; it binds to rat α1β1εδ and human α7 and α9α10 subtypes, 
indicating the importance of loops-I and -III residues in subtype selectivity.  
Phylogenetic analysis revealed functional organisation of Ω-neurotoxins 
independent of α-neurotoxins. Thus Ω-neurotoxins are a new, structurally 
distinct class of 3FTxs that, like α-neurotoxins antagonise nAChRs by binding 
to the ACh binding pocket, but through new set of functional residues. In this 
context, we explain the structure-activity studies and the phylogenetic analysis 
of Ω-neurotoxins as a “special case” of functional convergence that 
antagonises nAChRs, but with a profoundly novel functional site while 
retaining the compact three-finger fold. 
Thus, these studies significantly contribute to the field of snake venom 
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1.1 Venom research: A paradigm shift 
“All things are poison, and nothing is without poison; only the dose permits 
something not to be poisonous” – Paracelsus, Father of toxicology. 
  Venoms target vital physiological processes causing deleterious effects in 
the target animal. Among various lethal venomous animals, snakes are one of 
the most widespread and often encountered by humans. A recent WHO 
estimation says that at least 421,000 envenomings and 20,000 deaths occur 
worldwide from snake bite each year and warns that these figures may be as 
high as 1,841,000 envenomings and 94,000 deaths (WHO 2012 website 
update). 
Early research on animal venoms and toxins was focused mainly on 
identifying the biological and physiological effects of envenomation and the 
development of anti-venoms to neutralize the toxicity and adverse effects 
associated with the venoms (Kini, 2002). However, in the last few decades, the 
focus of venom research has been shifted to the isolation and subsequent 
characterization of individual toxins. This paradigm shift on animal toxins has 
revealed a far wider scope for the venom and its components, as specific 
research tools to better understand normal physiological processes at 
molecular level, as well as the discovery of excellent lead molecules for the 
novel drug design and therapeutics. Thus, venoms have provided intriguing 
insights on various areas of biology including immunology (therapies for 
envenoming) (Harrison et al., 2011; Williams et al., 2011), physiology and 




(Rowan and Harvey, 2011), structural biology (protein binding and 
interaction) (Dutertre and Lewis, 2010; Zouridakis et al., 2014) and 
pharmacology (drug discovery) (Harvey, 2014; King, 2011). 
During 70’s, the first drug was developed based on the structure of a snake 
venom toxin from Brazilian pit viper venom to treat high blood pressure. 
Curious to understand the drastic drop in blood pressure in the victims bitten 
by the snake, Brazilian and British researchers studied the effects of the venom 
in animals. This study led to the discovery of a peptide bradykinin potentiating 
peptide (BPP) that blocked the action of angiotensin-converting enzyme 
(ACE), which is necessary to maintain the blood pressure in the body (Ferreira 
et al., 1970a; Ferreira et al., 1970b). A smaller peptidomimetic was 
synthesized, which was one of the first of many ACE inhibitor drugs to treat 
patients with high blood pressure  and  is marketed as Captopril under the 
trade name Capoten (Patlak, 2004). Besides Captopril, drugs like eptifibatide 
and tirofiban are in the market that are also designed and developed based on 
the structure of snake venom proteins (of disintegrin family) and are used to 
prevent heart attacks. Eptifibatide is a cyclic heptapeptide designed based on a 
protein found in the venom of the south eastern pygmy rattlesnake (Sistrurus 
miliarius barbouri), whereas tirofiban is a peptidomimetic designed based on 
echistatin found in the venom of the saw-scaled viper (Echis carinatus). Both 
are antiplatelet drugs of the glycoprotein IIb/IIIa inhibitor class and are used 
since 1998, to treat acute coronary syndrome and in high-risk patients 




In the process of understanding the prevention of blood clots by the venom 
components of southern copperhead snake, Dr. Francis Markland, University 
of Southern California, discovered a dimeric disintegrin that prevents the 
platelet aggregation. In addition to the antiplatelet properties, this property of 
inhibiting cell to cell adhesion led to the rationale that this protein may prevent 
cancer metastasis through cell adhesion. This was further tested by various 
laboratory studies which resulted in the discovery of the venom protein, 
contortrostatin (Markland et al., 2001).  Contortrostatin prevented spreading of 
cancer cells and also inhibited the cancer cell signalling that promotes the 
formation of new blood vessels to support the spread of the cancer (Minea et 
al., 2005). Currently, vicrostatin, a chimeric protein developed on the basis of 
disintegrins - echistatin and contortrostatin, is being tested in animal models as 
an anti-cancer agent (Minea et al., 2012). Development will take place through 
the start-up company, Applied Integrin Sciences Inc (Harvey, 2014). Thus, 
snake venom components are being investigated for potential cancer fighting 
properties also. 
Further, snake venom components are also used as experimental tools to 
understand normal physiological processes such as neurotransmission 
(Albuquerque et al., 2009; Barber et al., 2013). The research on the paralysing 
effects of snake venom has led to the discovery of high affinity ligands with 
considerable specificity for various receptors involved in the 
neurotransmission. One such ligand, bungarotoxin, was helpful in the 
isolation of nicotinic acetylcholine receptors (nAChRs) and understanding of 




nAChRs and other receptors have been isolated from snake venom and 
characterized. The properties of these toxin ligands can be used to design 
various molecular tools to define the roles of various subtypes of receptors 
involved and as therapeutic agents or delivery systems to treat neurological 
disorders.  
These successful examples triggered the recognition that venoms could be 
the source of new medicines and research tools (Harvey, 1992, Lewis and 
Garcia, 2003, Fox and Serrano, 2007, Shaw, 2009, King, 2011, Koh and Kini, 
2012 and Takacs and Nathan, 2014). Our lab has been involved in 
characterization of novel toxins isolated from snake venoms, which have 
unique structures and pharmacological properties. These discoveries have not 
only contributed to the paradigm of “toxins to therapeutics”, but also have 
increased our understanding on protein folding, protein neo-functionalization, 
and normal physiology. 
Since this thesis describes characterization of a novel class of neurotoxins 
from snake venoms, here I present a brief introduction to venomous snakes, 
snake venom composition, molecular targets of snake venom components and 
their significance. 
1.2 Snakes: Venomous and non-venomous slithering serpents 
Snakes (class Lepidosauria, order Squamation) may have originated during 
cretaceous age, dating back to 100 to 120 million years. However, the 
evolution of venomous forms is thought to be recent, perhaps as recent as the 




than 3200 species of snakes that are documented, around 1300 are venomous 
(Namiranian and Hider, 1992). Venomous snakes belong to suborder 
Serpentes and are capable of producing venom from their highly modified 
salivary gland called venom gland. The venom is used primarily for 
immobilizing prey and defence against predators. During snake bites, venom 
is mechanically injected via hollow teeth called fangs. They belong to four 
families; Elapidae, Viperidae, Atractaspididae and Colubridae (Table 1.1). 
Table 1.1 Families of Venomous Snakes 
 
1.3 Snake venom: Deadly cocktail of multifaceted components 
Venom in is defined as, a secretion, produced in a specialised gland in an 
animal and delivered to a target animal through the infliction of a wound, 
which contains molecules that disrupt normal physiological or biochemical 
processes to facilitate its feeding or defence (Fry et al., 2012; Fry et al., 2009). 
Snake venom typically comprises a mixture of protein and non-protein 




components, such as amino acids, nucleic acids and neurotransmitters, 
whereas the protein components (usually the abundant and active part of 
venom) constitutes enzymatic and non-enzymatic proteins. 
1.3.1. Enzymatic snake venom proteins 
 
Figure 1.1 Common enzymes found in snake venom. (a) Class I PLA2. (b) 
Class II PLA2. (c) β-Bungarotoxin, a presynaptic toxin with PLA2 linked to Kunitz -type 
serine proteinase inhibitor. (d) Serine proteinase (TSVPA). (e) Group D prothrombin 
activator. (f) l-Amino acid oxidase. (g) PI metalloproteinase. (h) PIII metalloproteinase 
VAP2 (vascular apoptosis-inducing protein 2). (i) AChE. The structures of hyaluronidase 
and nucleotidases are not yet known. Abbreviations: CRD – cysteine–rich domain; DIS – 
disintegrin domain; EGF – epidermal growth factor domain; MP – metalloproteinase 
domain; PLA2 – phospholipase A2 subunit; SP – serine proteinase domain; SPI – serine 
proteinase inhibitor subunit. Figure 1.1 has been reproduced with permission from 





Snake venoms are rich in enzymes. There are about 20 enzyme families 
detected in snake venoms and 12 are known to be found in most of the snake 
venoms (Table 1.2) (R.C Hider et al 1992). Some of the common snake venom 
enzymes are metalloproteinases, hyaluronidase, phospholipase A2 (PLA2), 
nucleotidases (5΄-nucleotidase, ATPase, phosphodiesterase and DNase), 
acetylcholinesterase (AChE), and L-amino acid oxidase (LAAO) (Figure 1.1).  
Snake venom has been a treasure source for enzymologists not only for its 
richness of various enzymes but also for their functions and unique properties. 
Some of the snake venom enzymes are more active than the corresponding 
mammalian enzymes (Dudai et al., 1973).  In addition, few have weird 
properties, for example, snake venom L-amino acid oxidase is inactivated 
when stored in a frozen state and is completely reactivated by heating at pH 5 
(Curti et al., 1968). Therefore, these have been the proteins of interest for 
decades. However, enzymatic venom proteins are not under the scope of this 
thesis. As the focus is on the other class, non-enzymatic proteins, I present its 
description in the following sections. 
1.3.2. Non-enzymatic proteins 
Non-enzymatic proteins of snake venom facilitate immobilization of prey 
by binding to specific receptors, ion channels and enzymes to block their 
normal functions. They are usually rich in disulphide bridges which make 
them stable molecules. Some of the well identified families of non-enzymatic 
venom proteins are; Three-finger toxins (3FTxs) targeting various receptors 




receptors), enzymes (acetylcholine esterase and blood coagulation factors) and 
ion-channels (calcium ion-channels and proton gated acid sensing ion channels 
(ASICs)); Serine protease inhibitors (SPIs) or Kunitz-type protease 
inhibitors; C-type lectin-related proteins (CLPs), which have a variety of 
biological properties such as anticoagulant, procoagulant and 
agonists/antagonist effects on platelet activation (Morita, 2004); 
Helveprins/CRISPs, Cysteine-rich secretory proteins (CRISPs) that block 
smooth muscle contraction (Yamazaki and Morita, 2004); Sarafotoxins which 
act as vasoconstrictors on cardiac muscle and brain (Patocka et al., 2004); 
Waprins, Omwaprin that has antibacterial activity (Nair et al., 2007); 
Natriuretic peptides, that causes blood pressure reduction through 
vasodilation (McCleary and Kini, 2013); Bradykinin-potentiating peptides, 
inhibiting ACE causing low blood pressure;  Cobra venom factors; Vascular 
endothelial growth factors; Dendroaspins, which prevents platelet 
aggregation by binding to integrin via RGD motif (Oyama and Takahashi, 
2015); Vespryns, which induces hypolocomotion and hyperalgesia, e.g., 
ohanin (Pung et al., 2005); Nerve growth factors (NGFs) which induces 
nerve growth  and Veficolins, that has sequence homology to ficolin (a 
mammalian protein with collagen-like and fibrinogen-like domains) and 
proposed to affect platelet aggregation and/or initiate complement activation 
(OmPraba et al., 2010). 
 As this thesis deals with 3FTxs, I have briefly described 3FTx family in 




1.4 Three-finger toxin family (3FTx) 
The members of 3FTx family contain 57-82 amino acid residues with 4 or 5 
disulphide bridges (Dufton and Hider, 1988; Endo et al., 1991). These proteins 
are rich in disulfide bonds, >10% cysteines, therefore they are extremely stable 
to denaturation and proteolysis. 3FTxs have been identified in the venoms of 
elapids and colubrids (Pawlak et al., 2006; Pawlak et al., 2009) as well as 
described in the transcriptomes of viperids and atractaspiids (Jiang et al., 1987; 
Pahari et al., 2007; Terrat et al., 2013). These toxins have a distinct protein 
fold with three finger-like β-stranded loops extending from the central 
globular hydrophobic core, cross-linked with four conserved disulphide bonds 
(Figure 1.2), resembling three out stretched fingers, hence their names. Some 
3FTxs have a fifth disulphide bridge in the loop I or loop II. Some of them 
have also been found to exist and functional in the form of non-covalent (κ-
bungarotoxin and haditoxin) (Roy et al., 2010) or covalent dimers (irditoxin) 
(Pawlak et al., 2009), in which the monomers have distinct three-finger fold 
(Figure 1.2, D). The structurally conserved regions of 3FTxs such as the 
conserved cysteine pairs contribute to the proper folding and structural 
integrity of 3FTxs. Despite the similarity in the three-finger fold, the members 
of this family have diverse biological activities (Figure 1.3) (Kini, 2002). 
Therefore, 3FTx is a superfamily of, Neurotoxins, which antagonize muscle 
and various subtypes of nAChRs (Harvey et al., 1984; Trémeau et al., 1995) 
(Utkin et al., 2001; Nirthanan et al., 2003); Aminergic toxins, which were 
previously described to act on 
*
muscarinic AChRs (mAChRs) (Servent and 
                                                 
*
mAChRs are ACh receptors that are more sensitive to muscarine than to nicotine and they 




Fruchart-Gaillard, 2009) and recently described to be cross reactive on 
adrenergic and dopaminergic receptors (Blanchet et al., 2014); Fasciculins 
which are acetylcholine esterase inhibitors (Rodríguez-Ithurralde and Vincent, 
1994); Cytotoxins cause cytotoxicity by cell lysis, Cardiotoxins that at lower 
concentrations increase heart rate and kill the animal by cardiac arrest at 
higher concentrations (Bilwes et al., 1994; Dufton and Hider, 1988); β-
cardiotoxins, which bind to β1- and β2-adrenergic receptors (Rajagopalan et 
al., 2007); Calciseptines that block the L-type calcium channels (Albrand et 
al., 1995; de Weille et al., 1991); Ion channel blockers which block the ion 
channels such as  potassium channels (Lin et al., 2004); Platelet aggregation 
inhibitors like dendroaspin (McDowell et al., 1992) and another 3FTx with 
RGD sequence isolated from B. multicinctus venom (Shiu et al., 2004); 
Mambalgins (Diochot et al., 2012),; and  Hemextins (Banerjee et al., 2005b). 






Figure 1.2 Structural similarities of the members of three-finger toxin 
family. (a) Short chain toxin, erabutoxin a (1QKD); (b) Long-chain toxin, α-
bungarotoxin (2ABX); (c) cardiotoxin V4 (1CDT); (d) κ-bungarotoxin (1KBA), inset, 
dimer; (e) Non-conventional toxin, candoxin (1JGK); (f) fasciculin 2 (1FAS); (g) 
muscarinic toxin MT-2 (1FF4; R Menez et al., 2002);  (h) FS2 toxin (1TFS); (i) 
dendroaspin (1DRS). These 3FTxs share a similar structural fold; three β-sheeted ‘loops’ 
start from the core, the globular top of the molecule that contains all four conserved 
disulphide bridges. These β-sheeted loops are numbered right to left as loop I, II and III, 
respectively. The disulphide bridges are highlighted in green.  Some toxins, such as α-
bungarotoxin (b) and β-bungarotoxin (d) have the fifth disulphide bridge in loop II. In 
contrast, candoxin (e) has the fifth disulphide bridge in loop I. The Figure has been 







Figure 1.3 Functional sites of different three-finger toxins. The functional 
sites (highlighted in red) are located on different regions on the common three -finger 
motif of different three-finger toxins. (A) Neurotoxic site of erabutoxin a (1QKD), (B)  
Cytolytic site consisting of hydrophobic and cationic  residues, shown in white and red 
respectively, is located in all the three loops of cardiotoxin V4 (1CDT), (C) 
acetylcholinesterase inhibitor site of fasciculin (1FAS), (D) hypotensive site of FS2 
toxin (1TFS), (E) antiplatelet site of dendroaspin (1DRS) (F) Analgesic site recognizing 
neuronal nitric oxide synthase is located in the C-terminal tail of hannalgesin. The PDB 
code accession numbers are stated in parentheses. Three β-sheeted loops are numbered 
from right to left as loop I, loop II and loop III respectively.  The Figure 1.2 has been 
reproduced with the permission of Professor R. Manjunatha Kini, National 





Figure 1.4 Neighbour Joining tree for the three-finger toxin superfamily. 
Groups are Type A muscarinic toxins (M-A), Type B muscarinic toxins (M-B), Type C 
muscarinic toxins (M-C), synergistic toxins (S), Type I a-neurotoxins (Type I a). Type II 
a-neurotoxins (Type II a), j-neurotoxins (kap), Antiplatelet toxins (anti), L-type calcium 
channel blocking toxins (L), acetylcholinesterase inhibiting toxins (Acn), Type IA 
cytotoxins (Type IA cyto), Type IB cytotoxins (C-B), Type III a-neurotoxins (T-III), and 
orphan groups I–XX. Outgroup sequences (Q14210 and P35459) were removed from the 
final tree image, although they were included in the analysis to root the phylogeny. This 




Based on their sequence alignments and phylogeny, our lab identified 20 
different clades (I – XX) whose functional roles are yet to be determined and 
hence grouped these toxins as “orphan toxins” (Figure 1.4) (Fry et al., 2003a). 
Their intended interests notwithstanding, the ability of 3FTxs to affect a 
diverse range of molecular targets known so far, by involving just a few subtle 
changes in the functional sites makes them an exciting group of molecules to 
understand and study their structure-function relationships posing interesting 
challenges. Moreover, the large number of orphan toxins in this growing 
family of snake venom 3FTxs indicates that there are a significant number of 
toxins with unique pharmacological potencies which are yet to be investigated. 
Therefore, it will be interesting to elucidate the structure-function relationships 
of these orphan toxins. 
Among these various classes of 3FTx family, three-finger neurotoxins is the 
major class with more number of 3FTxs that are neurotoxic, and also this class 
is of main interest in this thesis. 
1.5 Three-finger neurotoxins 
Snake venom toxins that affect the cholinergic neurotransmission by 
antagonizing various subtypes of nicotinic acetylcholine receptors (nAChR) 
are referred as neurotoxins. They were the very first neurotoxins isolated and 
fully characterized and they constitute major part of 3FTx family. On the basis 
of their structural characteristics and pharmacological action, snake 
neurotoxins are broadly classified as α-neurotoxins or curaremimetic toxins, 




1.5.1 Curaremimetic toxins (α-neurotoxins) 
The pharmacological action of causing flaccid paralysis by this group of toxins 
was similar to that of an alkaloid arrow poison, curare (tubocurarine), used by 
South American Indians and hence the name. α-Neurotoxins bind to 
postsynaptic nAChRs at the skeletal muscle neuromuscular junction and 
inhibit neurotransmission. Even though the primary molecular target of α-
neurotoxins appears to be the muscle-type nAChR, some of them are also 
known to interact with other subtypes of nAChRs. Hence, while a 
classification of three-finger neurotoxins that interact with the muscle nAChR 
may be feasible from a purely structural stand-point, it must be remembered 
that α-neurotoxins are not a functionally homogenous group (Nirthanan and 
Gwee, 2004). Based on their amino acid sequence and/or 3D structures (Fry et 
al., 2003a), belong to the three-finger toxin (3FTx) superfamily of venom 
proteins. These monomeric α-neurotoxins are classified into two subclasses: 
Type-I (short-chain) α-neurotoxins comprise 57–62 amino acid residues and 
four conserved disulphide bridges in the core region, and  Type-II (long-chain) 
α-neurotoxins comprise 66–75 amino acid residues and a fifth disulphide 
bridge at the tip of loop-II (reviewed in (Kini and Doley, 2010)) (Table 1.3). 
Although both short- and long-chain α-neurotoxins block muscle-type 
nAChRs with similar nano-molar affinities (Kd ~10
9–1011 M)  (Servent et al., 
2000), only long-chain α-neurotoxins block neuronal α7, α9 and α9α10 
nAChRs with high affinity (Kd ~10




Table 1.2 Classification of α-neurotoxins 
 
Neurotoxins with the fifth disulphide in loop-I were characterized in the past 
15 years. Most of them show micromolar toxicity, which explains their 
classification as ‘weak toxins’ (Utkin et al., 2001). However, candoxin from 
Bungarus candidus blocks α7 and muscle nAChRs with nanomolar affinity 
(Nirthanan et al., 2002). Therefore, we classified toxins with the fifth 
disulphide bond in the first loop as non-conventional toxins (Nirthanan et al., 
2003). Candoxin binds to muscle (α1β1γδ) (IC50 = ∼10 nM) in a reversible 
manner and neuronal α7 (IC50 = ∼50 nM) in poorly reversible manner, clearly 
showing diverse functional profiles for the two nAChR subtypes. Denmotoxin 
was isolated from the venom of a colubrid snake, Boiga dendrophila 
(mangrove catsnake). Another neurotoxin, denmotoxin also has a fifth 
disulphide bond at the tip of loop-I, but has no disulphide bond at loop-II. This 
toxin was characterised by its long N-terminal tail compared to long-chain 
toxins. Functionally, denmotoxin exhibited species specificity towards avian 


































































































































































































































































































































































































































































































1.5.2 κ-neurotoxins and other dimeric three-finger neurotoxins; 
Most characterized neurotoxins exist as monomers. However, ҡ-neurotoxins 
and haditoxin are non-covalent homodimers (Chiappinelli et al., 1996; Grant 
et al., 1998). ҡ-neurotoxins exist as non-covalently linked dimers composed of 
long-chain α-neurotoxins (Grant and Chiappinelli, 1985), which confers them 
new functional properties. For example κ-bungarotoxin, isolated from 
Bungarus multicinctus, bind specifically to neuronal (α3β4) nAChR (Grant 
and Chiappinelli, 1985).  Structurally their monomers are 66 - 70 amino acid 
residues long with the fifth disulphide bridge located in loop-II, similar to 
long-chain α-neurotoxins (Figure 1.1, d). In comparison with long chain α-
neurotoxins, κ-neurotoxins recognize α3β2 and α4β2 subtypes but not the 
α1(Figure 1.1, d inset) (Chiappinelli et al., 1996). 
In contrast, haditoxin is structurally similar to short-chain neurotoxins and 
efficiently blocks muscle-type nAChRs and α7 nAChR. Haditoxin also 
interacts with α3β2 and α4β2 nAChRs at very high concentrations (Roy et al., 
2010). 
We published the first report of a disulphide-bonded covalent heterodimeric 
neurotoxin: irditoxin. This neurotoxin is found in Boiga irregularis venom and 
uniquely inhibits bird-specific muscle-type nAChRs (Pawlak et al., 2009). 
Utkin and colleagues described homomeric and heteromeric disulphide-
bonded dimers in Naja kaouthia venom (Osipov et al., 2008; Osipov et al., 




structure and function. Therefore, 3FTx are a new class of nAChR antagonists 
and have diverse pharmacological profiles. 
 
Figure 1.6 Structures of non-conventional three-finger neurotoxins. A) 
Candoxin [1JGK] (pink spheres highlighting the 5th disulphide bridge at loop-I, B) 
Denmotoxin [2H5F] from colubrid venom(4 conserved and 5th disulphide bridge at loop-
I are shown in yellow sticks; purple spheres highlighting the extended c-terminal tail), 
C) Haditoxin [3HH7] (non-covalent dimer of short-chain monomers), D) Irditoxin 
[2H7Z] (Covalently linked heterodimeric three-finger toxins found in colubrid venom). 
The PDB code accession numbers are stated in parentheses. Structures are made with 
the aid of the PyMOL software (except for Haditoxin (Roy et al., 2010)).  
 
1.6 α-Neurotoxins: Delineation of molecular determinants 
Extensive chemical modification and site directed mutagenesis studies in 
parallel with the comparison of growing sequence data in 1970s enabled the 
elucidation of structure function relationships of α-neurotoxins. At that stage 




identified. Further, the developments in assessing molecular structures with 
determination of crystal structure of erabutoxin b, a short-chain neurotoxin 
from sea krait venom, Laticauda semifasciata(Low, 1976; Tsernoglou and 
Petsko, 1976) has enabled reinterpretation of previous chemical modification 
and sequence data facilitating the visualization of the reactive site of 
neurotoxin in three-dimensional structure. By X-ray crystallography and 
NMR, the structure of α-bungarotoxin, a typical snake long-chain α-
neurotoxin was determined both alone and in complex with peptides from a 
region of the AChR ligand-binding site known as loop C (Love and Stroud, 
1986; Scherf et al., 1997; Zeng et al., 2001), a structural element essential for 
agonist and antagonist binding (Sine, 2002; Taylor et al., 2007; Thompson et 
al., 2010). The ability of α-bungarotoxin to form complexes with loop C 
peptides suggested that loop C was a primary site for α-bungarotoxin binding 
in the intact AChR, which evident by the observations that N-linked 
glycosylation within loop C eliminates high-affinity binding in animals 
resistant to α-bungarotoxin (Barchan et al., 1992; Kreienkamp et al., 1994; 
Neumann et al., 1986). In addition, studies of site-directed mutations showed 
that loop C is the most important of the multiple binding site loops in 
conferring high affinity for α-neurotoxins (Fruchart-Gaillard et al., 2002; 
Levandoski et al., 1999). The crystal structure of another long chain α-
neurotoxin, α-cobratoxin, bound to the pentameric †acetylcholine binding 
                                                 
†
 Acetylcholine binding protein (AChBP) is secreted by snails into cholinergic synapses, 
where it modulates transmission by binding acetylcholine (ACh). Sequence alignment 
revealed high similarity to the extracellular domains of the ligand-binding subunits of the 
nicotinic acetylcholine receptor (nAChR). Due to the limitations in the purification of 
membrane bound nAChRs, soluble AChBP has been a convenient option for structural studies 
of nAChRs. The crystal structure of the AChBP homopentamer indeed provides a valuable 




protein (AChBP), from the snail Lymnaea stagnalis, solved at an overall 
resolution of 4.2A°, revealed the orientation of the toxin backbone relative to 
the ligand-binding site (Bourne et al., 2005). This structure analysis also 
showed that loop C of AChBP lodged between loops I and II of α-cobratoxin. 
However, the resolution of 4.2 Å (1 Å = 0.1 nm) and the low sequence 
homology between AChBP and nAChR (25%) limited the accuracy with 
which inter-residue interactions and the α-neurotoxin-induced structural 
changes in relation to AChR function could be analysed. The structure of α-
bungarotoxin bound to the monomeric α1 subunit extracellular domain was  
determined by X-ray diffraction at a resolution of 1.94 Å (Dellisanti et al., 
2007), but the absence of the complementary subunit of the ligand-binding site 
posed limitations in the accuracy of orientation of the toxin and the inter 
residue interactions. In 2013, the crystal structure of α-bungarotoxin bound to 
α7 receptor ligand-binding domain chimaera enabled the identification of 
inter-residue interactions that stabilize α-neurotoxins bound to their nicotinic 
receptor targets as depicted in Figure 1.5 (Huang et al., 2013) and the findings 
were consistent with the previous structure studies. Unlike long-chain α-
neurotoxins, short-chain α-neurotoxins had no or poor affinity towards AChBP 
and hence the insights to ligand-receptor interaction in relation to short-chain 
α-neurotoxins were pursued with extensive mutational studies and molecular 
modelling. 
 In 1990s Menez and co-workers, delineated the functional sites of 
erabutoxin-a (Pillet et al., 1993; Tremeau et al., 1995) and α-cobratoxin (Antil-
                                                                                                                                
the nAChR. Furthermore, crystal structures of complexes of AChBP with various agonists and 




Delbeke et al., 2000; Antil et al., 1999), classical examples of short- and long 
chain neurotoxins respectively, through systematic and well-targeted site-
directed mutagenesis. This exhaustive mutational analysis studies, revealed 
that both short-chain and long-chain α-neurotoxins recognize the Torpedo or 
muscle (α1)2βγδ receptor by a common binding core consisting number of 
structurally equivalent residues, including Lys23/Lys27, Asp27/Asp31, 
Arg33/Arg33 and Lys49/Lys47, as well as Trp25/Trp29 and Phe29/Phe32 
(numbered as in cobratoxin/erabutoxin). Besides these residues, the carboxy 
terminal tail of α-cobratoxin and in contrast, the residues of loop-I in 
erabutoxin-a have also been shown to have role in binding. Interestingly, 
unlike erabutoxin, α-cobratoxin binds to both muscle (α1)2βγδ receptor and α7 
neuronal receptor and Antil-Delbeke et al. and Antil et al. have identified the 
residues in α-cobratoxin that are involved in the binding to neuronal α7 
nAChR. α-Cobratoxin binds to both Torpedo (α1) and α7 receptors using some 
common residues (Trp25, Asp27 and Arg33). Furthermore, it also uses distinct 
residues which are receptor specific, such as Ala28, Lys35 and Cys26-Cys30 
for recognition of the α7 receptor and Lys23 and Lys49 for the Torpedo 
receptor. In addition, the cyclic structure formed by the fifth disulphide bridge 
at the tip of the second loop of α-cobratoxin has been reported to be essential 
for the toxin to interact with α7 receptor (Antil-Delbeke et al., 2000). In 2005, 
the co-crystallisation studies of α-cobratoxin with AChBP and mutational 
analysis provided much more updates on the receptor specific interactions of 
the toxin, as tabulated in Table 1.4 and depicted in Figure 1.5 (Bourne et al., 




Phe29, Lys35, ‡Arg36(Val39) and ‡Phe65(His68) caused an affinity decrease 
of more than five- or seven-fold to α7 nAChR (Fruchart-Gaillard et al, 
2002).This result indicated that these residues are critical to interact with α7 
nAChR. Whereas, in erabutoxin-a, the receptor-specific residues are His6, 
Gln7, Ser8, Ser9 and Gln10 of loop I and Tyr25, Gly34, Ile36 and Glu38 of 
loop II (Teixeira-Clerc et al., 2002; Tremeau et al., 1995). Therefore, 
neurotoxins appear to establish contacts with key invariant residues on the 
nAChR utilizing common binding core and interact with subtype-specific 
receptor residues using other toxin-specific residues (Menez A, Servent D et 
al., 2002) and the functionally important residues of both short-chain and long-
chain α-neurotoxins to bind to the Torpedo or muscle (α1)2βγδ receptor were 
all found to be located on the concave surfaces in 3D-structure orientation of 
toxins (Antil et al., 1999; Ducancel et al., 1996; Tremeau et al., 1995). Besides 
the residue specific function, the conformational dynamics in three-finger 
folds of short-chain and long-chain α-neurotoxins were also shown to have 
some functional significance (Menez, 1998). For instance, the presence of an 
extra disulphide bridge at the tip of loop II, a longer C-terminus tail, a shorter 
loop I in long-chain toxins and the absence of the same in short-chain toxins 
was attributed to the high affinity binding of long-chain α-neurotoxins, but not 
short-chain α-neurotoxins, to neuronal α7 nAChRs (Bourne et al., 2005; 
Fruchart-Gaillard et al., 2002; Servent et al., 1997). In contrast to the 
involvement of loop I in the short-chain toxin erabutoxin-a, mutations in the 
loop I residues of the long-chain toxin α-cobratoxin did not confer decrease in 
the affinity of the toxin to nAChR, suggesting that loop-I residues are not 
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functionally important in α-cobratoxin  (Antil-Delbeke et al., 2000; Antil et 
al., 1999). 
Table 1.3 Intermolecular interactions of α-cobratoxin a 
 
a
Within a 4.5A° distance between atoms from each partner in the complex 
b
Residue substitutions in Bgtx are indicated in parentheses. 
c
Indicated in bold are those residues in Cbtx and in the a7 receptor (AChBP numbering) whose 
mutations cause an affinity decrease of more than five- and seven-fold, respectively (Fruchart-





Figure 1.7 The Cbtx–AChBP complex interfaces. (A) Close-up view of the 
bound Cbtx molecule. The Cbtx residues (black labels) that interact with the principal 
and complementary faces of the AChBP subunit interface are in yellow and cyan/green, 
respectively. The AChBP residues in the complementary face of the interface are in 
white (blue labels). (B) Structural comparison of (left) the Cbtx-bound loops Ser182–
Glu193 of AChBP and (right) the Bgtx-bound 13-mer peptide (structure 1HC9; Harel et 
al, 2001). The molecular surfaces of the complex interfaces are shown in transparency. 





Figure 1.8 Inter-residue interactions between α-box and the α7/AChBP 
chimaera. (a) Stereo view of key residue side chains between the tip of finger II of α -
box (purple) and the principal subunit of the α7/AChBP chimaera (cyan). (b) Stereo view 
of key residues between finger I of α-box (purple) and the backside of loop C of the 
α7/AChBP chimaera (cyan). (c) Stereo view of key residues between finger II of α -box 
(purple) and the complementary subunit of the α7/AChBP chimaera (orange). Figure 1.5 




In addition, only three residues of loop I of α-cobratoxin were found to be 
involved in intermolecular interactions with AChBP (Bourne et al., 2005). 
This observation was attributed to the considerably shorter loop-I in α-
cobratoxin when compared with that of erabutoxin-a, which possibly makes it 
inaccessible to the receptor surface and prevents its involvement in interacting 
with the receptor (Servent et al., 1997). In 2001, the cyclic conformation of the 
tip of loop II was revealed to be a dynamic entity in the NMR analysis of the 
solution structures of α-bungarotoxin alone and in complex with short cognate 
peptides of the nAChR toxin-binding region (Zeng et al., 2001). This dynamic 
nature of the cyclic conformation of the tip of loop II due to fifth disulphide 
bridge was speculated to enable the long-chain α-neurotoxins to accommodate 
flexible structural deviations and adopt different conformations to bind diverse 





of the fifth disulphide bridge of loop-II of α-





 of complementary (non-principal) face of AChBP (Bourne et 
al., 2005). This last point indicates the direct involvement of their side-chain 
interactions in binding to the receptor. In contrast, the short-chain α-
neurotoxins, atypical long-chain toxins and non-conventional toxins (with a 
fifth disulphide bridge in loop I), lacks this fifth disulphide bridge in loop II 
and  have weaker affinities, in micromolar concentrations for the neuronal α7 
nAChR (Poh et al., 2002; Servent et al., 1997; Utkin et al., 2001). However, 
candoxin (isolated from Bungarus candidus venom) blocks neuronal α7 
nAChRs in low nanomolar concentrations, (Nirthanan et al., 2002). Therefore, 




determinants to interact with the neuronal α7 nAChR (Nirthanan and Gwee, 
2004). It is evident from these revelations that there is no single designated 
location for the interaction sites. Therefore, detailed structure-function 
characterisation of identified and new members of 3FTx family can shed light 
on the undetermined means of interaction of neurotoxins to propagate 
receptor-subtype specificity and affinity towards nAChRs.  
In this context, the importance of studying nAChRs and the significance of 
snake venom research in understanding the function of nAChRs are detailed in 
further sections. 
1.7 Nicotinic acetylcholine receptors (nAChRs) 
Nicotinic acetylcholine receptors (nAChRs) are the ligand-gated ionotropic 
receptors that are activated by the endogenous neurotransmitter acetylcholine 
(ACh) facilitating cholinergic neurotransmission both in central and peripheral 
nervous system. nAChRs are expressed by both neuronal and non-neuronal 
cells (e.g., muscular and other non-neuronal cells) throughout the body 
(Albuquerque et al., 1997; Dani and Bertrand, 2007; Eglen, 2005; Gotti and 
Clementi, 2004). The nicotinic receptors can be activated not only by 
endogenous agonist, acetylcholine but also by nicotine—hence the name 
"nicotinic”. This distinguishes the nicotinic receptors from muscarinic 
receptors, which are activated by muscarine, an alkaloid found in some 
mushrooms but not nicotine. 
The knowledge of nAChRs originated through the combination of two 




Lindstrom et al., 1979; Noda et al., 1982; Noda et al., 1983; Popot and 
Changeux, 1984)). The first was the discovery of Torpedo electric organ that 
expresses nAChRs at densities that approach a crystalline array to produce an 
electric pulse to stun its prey (Kistler and Stroud, 1981; Sobel et al., 1979). 
The second was the finding of α-bungarotoxin (α-BGT), a krait snake venom 
component that binds to muscle-type nAChRs with irreversible high affinity to 
mediate debilitating paralysis at the neuromuscular junction (Albuquerque et 
al., 1974; Barnard et al., 1977; Fertuck and Salpeter, 1974; Lee, 1979). With 
the integration of these diverse findings, the usage of α-BGT affinity columns 
for purification of nAChRs from detergent-solubilized electric organs came in 
to practice (reviewed in (Dolly and Barnard, 1984). Further, the identification, 
cloning, and sequencing of genes responsible for encoding these receptors 
revealed that the Torpedo nAChR subunits are closely related to an extended 
family of canvas that in humans encode 16 structurally homologous subunits. 
Now the studies have provided a consensus view of nAChRs as the 
transmembrane pentameric receptors made up of five subunits arranged 
around the central axis along which the ion channel lies as shown Figure 1.6 A 




Figure 1.9 Basic structure of nicotinic acetylcholine receptor (nAChR). 
A) Schematic representation of receptor subunits arranged around a central cation-
conducting pore. The ligand binding sites are formed at the interface of two subunits. B) 
Illustration of a single nAChR subunit embedded in the membrane.  C) The electron-
microscopy structure of the Torpedo nAChR is from Unwin (Unwin, 2005), and images were 
generated using the UCSF-chimera program with coordinates obtained from the 1OED.pdb. 
Approximate dimensions of the intact Torpedo receptor are given. The α-subunits are shown, 
where ribbons designate the secondary structures of the primary sequence. The extracellular 
domain is largely β-sheets and all transmembrane (denoted as M) domains are α-helices. The 
cytoplasmic domain is depicted as a large α-helix. The C-loop harbouring the Cys-Cys pair 
that projects from the extracellular domain core-β structure to surround an agonist ligand is 
shown. The entire receptor complex with a solid surface is shown to the right. The Figure 1.9 
has been adapted from (Albuquerque et al., 2009; Kabbani et al., 2013)and modified 
accordingly. 
These nAChRs are allosteric transmembrane glycoproteins with a molecular 
weight of ~ 290 kDa that belong to the 
§
Cys-loop receptor family and its 
subunits are characterised by the following features which are described in the 
order of their arrangement from N-terminus to C-terminus; 
                                                 
§
Cys-loop receptor family, also  includes glycine receptors, 5-hydroxytryptamine type 3 (5-
HT3) serotonin receptors, γ-aminobutyric acid type A (GABAA) and GABAC receptors and 





 Large conserved extracellular NH2-terminal domain of ~200 amino 
acids; the occurrence of a cysteine-loop (Cys-loop) defined by two 
cysteines (Cys) in the first extracellular domain, which in the 
mammalian subunits are separated by 13 intervening amino acids. 
Subunits are further classified into α- and non-α subunits based on 
the presence of a Cys-Cys pair(residues 191–192 in Torpedo α1) 
near the entrance to TM1, which is required for agonist binding 
(Karlin et al., 1986). 
 Conserved, α-helical three transmembrane (M) domains (M-I to M-
III);  
 A cytoplasmic loop between M-III and M-IV and amino acid 
sequence; and 
 A fourth α-helical transmembrane domain (M-IV) with a relatively 
short and variable extracellular COOH-terminal sequence.  
Based on the location of transmembrane domains relative to each other, this 
arrangement forms the basis for the classic designation of a 3+1 configuration. 
Depending on their major site of expression in the organism nAChRs are 
subdivided into muscle and neuronal subtypes (Figure 1.7) and they are named 
according to their subunit compositions. These nAChRs are allosteric 
transmembrane glycoproteins with a molecular weight of ~ 290 kDa that 
belong to the 
**
Cys-loop receptor family. The subunits are characterised by the 
                                                 
**
Cys-loop receptor family, also  includes glycine receptors, 5-hydroxytryptamine type 3 (5-
HT3) serotonin receptors, γ-aminobutyric acid type A (GABAA) and GABAC receptors and 





following features which are described in the order of their arrangement from 
N-terminus to C-terminus; 
 Large conserved extracellular NH2-terminal domain of ~200 amino 
acids; the occurrence of a cysteine-loop (Cys-loop) defined by two 
cysteines (Cys) in the first extracellular domain, which in the 
mammalian subunits are separated by 13 intervening amino acids. 
Subunits are further classified into α- and non-α subunits based on 
the presence of a Cys-Cys pair(residues 191–192 in Torpedo α1) 
near the entrance to TM1, which is required for agonist binding 
(Karlin et al., 1986). 
 Conserved, α-helical three transmembrane (M) domains (M-I to M-
III);  
 A cytoplasmic loop between M-III and M-IV and amino acid 
sequence; and 
 A fourth α-helical transmembrane domain (M-IV) with a relatively 
short and variable extracellular COOH-terminal sequence.  
Based on the location of transmembrane domains relative to each other, this 
arrangement forms the basis for the classic designation of a 3+1 configuration. 
Depending on their major site of expression in the organism nAChRs are 
subdivided into muscle and neuronal subtypes (Figure 1.7) and they are named 






Figure 1.10 Prominent subtypes of nicotinic acetylcholine receptors.Five 
homologous subunits constituting muscle nAChR with the stoichiometry of both adult 
and fetal forms, is schematically represented. The interface between two subunits 
inhabits the ACh binding site, which has been denoted as the drop-like shapes in 
different subtypes. Neuronal (heteropentameric) nAChRs along with their distribution 
details are shown, where α5 and β3 may occupy only positions comparable to β1 in which 
they do not participate in forming ACh binding sites, whereas α6 can participate  in 
forming ACh binding sites and also assemble nAChRs in association with α3 and α4 
subunits. As a typical example of neuronal homopentameric nAChRs α7 receptor 
subtype is represented. α7α8 heteromers can exist only in chickens and α9α10 
heteromers have also been found in mammals. Figure 1.10 has been adapted from 




1.7.1 Muscle type nAChRs 
Muscle nAChRs are the heteropentamers, made up of five subunits 
consisting of one α1 and four non-α subunits named β1, δ, γ, and ε. There are 
only two receptors that are constructed from this complex subunit pool, one 
subunit is α1, β1, δ, and γ forming the adult- muscle type nAChR, as this 
subunit composition has been witnessed in the adults, whereas the other 
subunit composition is α1, β1, δ, and ε, forming the fetal-muscle type nAChR, 
which is seen in the early stages of fetus (Figure 1.7, D).  Each of these 
subunit compositions are arranged in the stoichiometry of 2:1:1:1 :: α:β:γ:δ/ε. 
There are two non-identical ACh-binding sites located at the interfaces 
between the α-subunits and its neighbouring non-α subunits in muscle 
nAChRs. The muscle nAChRs in the neuromuscular junction (NMJ) are the 
primary target of postsynaptic three-finger neurotoxins. 
1.7.2 Neuronal nicotinic acetylcholine receptors 
Neuronal nAChRs were named so, as they were cloned from neuronal like 
cell lines (pheochromocytoma cell line, PC12, or brain-derived cDNA 
libraries). The subunits of neuronal nAChRs can assemble into various 
possible combinations to form homopentameric and heteropentameric 
nAChRs (Millar and Harkness, 2008; Millar and Gotti, 2009; Wu and Lukas, 
2011) (Figure 1.6). However, not all subunit combinations produce functional 
receptors and only a few combinations have been shown to possess biological 
importance (Millar and Gotti, 2009). Till date, there are about seven functional 




libraries and has not been found in mammals (Dani and Bertrand, 2007; Gotti 
and Clementi, 2004; Hogg et al., 2003)), and three non-α subunits (termed β2, 
β3, and β4) which have been cloned from neuronal tissues. Most of these 
receptor subtypes are present both pre- and post-synaptically in the NMJ and 
are also expressed by neurons of the central and peripheral nervous systems. 
However, there are numerous evidences that many of these nAChRs are 
expressed by many non-neuronal cell types in the body (Conti-Fine et al., 
2000; Gahring and Rogers, 2005; Kawashima and Fujii, 2003; Kurzen et al., 
2007; Sharma and Vijayaraghavan, 2002). For instance, some receptors (such 
as α7, α9, and α10) are involved in the regulation of signalling mechanisms 
used by sensory epithelia and other non-neuronal cell types.  
Receptor nomenclature in the nAChR area has been derived from classical 
pharmacology approaches including their sensitivity to snake toxin, which was 
delineated by using radio ligand binding (Clarke and Reuben, 1996). Neuronal 
nAChRs have been divided into two main subfamilies; α-bungarotoxin-
sensitive and α-bungarotoxin-insensitive nAChRs. The α-bungarotoxin-
sensitive nAChRs have low affinity for [
3
H] (-)-nicotine and can be 
homomeric (α7, α8 and α9) or heteromeric (α7α8 and α9α10) receptors. While 
the α-bungarotoxin-insensitive nAChRs are heteromeric combinations of α- 
(α2 – α6) and β- (β2 – β4) subunits (Gotti et al., 2006) and have high affinity 
for [
3
H] (-)-nicotine. There are five identical ACh-binding sites in homomeric 





1.7.3 Significance of nAChRs 
 The nAChRs have been recognized as important players in modulation and 
synaptic transmission in both central and peripheral nervous system. Neuronal 
nAChRs are involved in complex brain functions, such as memory, cognition 
and attention. In central nervous system, these nAChRs are involved in 
regulating processes such as neurotransmitter release, cell excitability and 
neuronal integration. Hence, nAChRs have been found to be potential 
therapeutic targets for various neuronal disorders such as, cognitive 
dysfunction/attention disorders, neurodegenerative disorders such as 
Alzheimer's (α7, α4β2) (reviewed in (Woodruff-Pak and Gould, 2002)) and 
Parkinson’s disease (α6,β5,α4β2) (Quik et al., 2012), pain (α4β2, α9α10) 
(reviewed in (Umana et al., 2013)), Schizophrenia (α7) (reviewed in 
(Woodruff-Pak and Gould, 2002), depression, epilepsy, smoking cessation and 
anxiety. The existence of functional non-neuronal nAChRs has long been 
known, and recent studies indicate that they might have important roles with 
regard to cell proliferation, angiogenesis, apoptosis or immunology 
(Kawashima and Fujii, 2008; Ulloa, 2005). Related to these functions, in the 
recent years, many studies have provided the evidence of nAChRs as 
therapeutic targets of various types of cancer (Russo et al., 2014). For 
instance, the proliferation of airways epithelial cancer cells and pancreatic 
cancer cells may be under the control of α7-nAChR, while breast cancer cells 
and colon cancer cells are regulated by α9-nAChR. Therefore, inhibition of 
α9- nAChR [polyphenol (-)-epigallocatechin-3-gallate] diminishes breast 




proliferation (Reviewed in (Russo et al., 2014) . Therefore, understanding the 
physiology of nAChR subtypes in terms of their complex in-vivo distribution 
and function (in association with various disorders) are of high significance.  
1.8 Ligands and ligand binding site of nAChRs 
Acetylcholine (ACh) is the traditional endogenous agonist of nicotinic 
acetylcholine receptors. Nevertheless, the described nAChRs ligands 
comprises of both agonists and antagonists. Agonists bind to the receptor on 
the orthosteric site and potentiate the receptor activity eliciting response. In 
contrast, antagonists when bound to receptor cause depression of receptor 
activity and prevent the receptor activation. Some ligands are also described to 
bind to sites other than orthosteric called allosteric site. 
Agonists and agonist binding site: With various affinity labelling (Reiter et 
al, 1972; Kao et al, 1984; Galzi etal, 1990; Middleton and Cohen, 1991), 
crosslinking and mutagenesis studies (for a review see, Karlin, 2002) agonist 
binding site is identified to be located in the interface between the subunits of 
nAChRs. With further photo labelling and mutagenesis experiments it was 
inferred that the principal component of the binding pocket is formed by the α-
subunit and the complementary component of the binding pocket is formed by 
the non α-subunits (Wang et al, 2000). Although the nAChR has not yet been 
crystallized, compelling inferences about its tertiary and quaternary structures 
have been derived from detailed structure studies on their soluble structural 
homolog (Brejcet al, 2001; Smith et al, 2001, Taylor et al, 2000; Changeux 
and Edelstein, 2001; Grutter and Changeux, 2001; Karlin, 2002), namely the 




synapses. The analysis of the AChBP binding site is consistent with the 
experimental findings about the ACh binding site on the nAChRs (Bourne et 
al., 2005; Fruchart-Gaillard et al., 2002; Huang et al., 2013). 
 ACh binding site of nAChRs is a hydrophobic pocket formed at the interface 
between adjacent subunits (Figure 1.7 A). In all cases, α subunit (α1, α2, α3, 
α4, α6, α7, or α9) forms the “principle” “front” or “positive” side of the 
binding site, where the Cys-Cys pair is required. Whereas the “non-principle” 
“back” or “negative” face of the agonist-binding site is formed by at least three 
amino acids of each the α10, β2, β4, δ, γ, or ε subunits. The other subunits (α5, 
β1, and β3) are not involved directly in the formation of the agonist binding 
site and can assemble in the receptor complex in the fifth subunit positions. 
The majority of the “positive” face in agonist binding pocket is contributed by 
a loop in the α-subunit termed as the C-loops (Figure 1.9 Band Figure 1.11) 
containing the Cys-Cys pair at its apex. Along with the Cys-Cys pair, the other 
critically required residues for the ligand binding are predominantly 
hydrophobic aromatic amino acids including αTyr93, αTrp149, αTyr190, and 
αTyr198 (Torpedo α subunit numbering)(Celie et al., 2004; Karlin et al., 1986; 
Sine and Engel, 2006). Whereas on the “negative” face, Lys112, Met114, and 
Trp53 (also Torpedo numbering) are the major residues that contribute to 
ligand binding.  Despite their definition as α subunits, α5 and a10 subunits do 
not bind agonists because the key residues required for agonist binding 
previously described are not conserved in these α subunits. 
Amino acid residues from the α-subunit contribute to the formation of loops 




(Figure 1.7 A). In addition, the neighbouring subunit (δ, or γ in muscle and α 
or β subtypes in neuronal receptors) residues contribute to loops D, E and F 
(forming the complementary component) of the ACh binding pocket (Figure 
1.7 A) (Changeux and Edelstein, 1998; Corringer et al, 2000; Arias, 2000; 
Itier and Bertrand, 2001). Therefore, hetero-pentameric muscle nAChR has 
two different ligand binding sites (α/δ and α/γ) with distinct affinities for 
nicotinic antagonists (Corringer et al, 2000), whereas the homopentameric α7 
receptor offers five identical ligand binding sites (Palma et al, 1996; Itier and 
Bertrand, 2001; Yakel, 2010). 
There are also several agonists that can interact with nAChRs at allosteric 
sites other than the classical ACh-binding site. Some examples of allosteric 
nAChR agonists are amyloid β peptide (Dineley et al., 2002; Pettit et al., 
2001), the cannabinoid anandamide (Oz et al., 2003; Spivak et al., 2007) and 
the nicotinic allosteric potentiating ligands (APLs). APLs increase nicotinic 
functions in the brain by sensitizing the receptor activation by the endogenous 
agonist(s). These APLs include drugs like physostigmine and galantamine 
which were approved for treatment of mild-to-moderate Alzheimer’s 
syndrome around 10-12 years ago (Shaw KP, et., al., 1985, Sherby SM, et., al., 
1985) (Pereira EFR, et., al., 1994, 2002).   
The agonist bound receptor conformation facilitates the channel opening, 
indicating that the protein structure has to be conserved for its proper function 
to accommodate rapid conformational change. The failure to do so (mutations 




myasthenia syndromes and some forms of epilepsy (Engel, 1994; Hogg et al., 
2003; Marini and Guerrini, 2007; Steinlein, 1998; Steinlein, 2002).  
 
Figure 1.11 Structure of the acetylcholine (ACh)-binding site on theα7 
nicotinic acetylcholine receptor (nAChR). A) Schematic representation of the 
ACh-binding site, illustrating amino-acid residues that participate in ligand binding.  The 
grouping of these amino-acid residues into loops A, B and C (the principal component) 
and loops D, E and F (the complementary component) are shown. B) Model of the α7 
nAChR obtained by comparative modelling, using the X-ray crystallography structure of 
ACh-binding protein in the presence of nicotine as a template (Celie et al., 2004). 
Residues identified by biochemical labelling are shown. For clarity, only two monomers 
are represented. Amino-acid residues of the principal side of the binding site are shown 
in green, and those of the complementary side are shown in beige. Nicotine is depicted in 
red. Figure 1.11 and its legend have been reproduced from (Changeux, 2010). 
 
Antagonists and their binding sites: Antagonists block or dampen the agonist-
mediated response of a receptor. Antagonists mediate their effects by binding 
to the orthosteric (competitive antagonists) or to allosteric sites (non-
competitive antagonists). 
Competitive antagonists reversibly bind to receptors at the same site as the 




antagonists "compete" for the same binding site on the receptor. Once bound, 
an antagonist will block the agonist binding. In functional assays using 
competitive antagonists, a parallel rightward shifts of agonist dose–response 
curves with no alteration of the maximal response is observed. Some examples 
of competitive antagonists of nAChRs are structurally complex alkaloids (e.g., 
MLA, d-tubocurarine, and DHβE). In addition, several potent competitive 
antagonists are small peptides (e.g., α-neurotoxins and α-conotoxins). 
The term "non-competitive antagonism" in nAChRs is used to describe the 
phenomena, where an antagonist binds to an allosteric site of the receptor. 
Unlike competitive antagonists, which affect the amount of agonist necessary 
to achieve a maximal response but do not affect the magnitude of that maximal 
response, non-competitive antagonists reduce the magnitude of the maximum 
response that can be attained by any amount of agonist. This property earns 
them the name "non-competitive" because their effects cannot be negated, no 
matter how much agonist is present.  
Although the nicotinic acetylcholine receptor (nAChR) has not yet been 
crystallized, compelling inferences of the existence of allosteric sites have 
been derived from extensive biophysical, biochemical, and microscopic 
investigations. A well-characterized domain for binding non-competitive 
inhibitors (NCIs) has been identified on the M2 transmembrane domains of the 
pore (Utkin et al., 2000). In 2007, experimental data for the presence of a  
binding site on non-α-subunit interfaces of heteromeric neuronal nAChRs was 
provided by the study of galantamine and non-competitive inhibitor (NIC) 




low-affinity binding sites has been found at the lipid-protein interface of the 
AChR (Reviewed in (Arias, 1997). Therefore, neither the mechanisms of 
action nor the sites of interaction of many NICs have been unequivocally 
determined. Some examples of NICs are bupropion ((Alkondon and 
Albuquerque, 2005; Mansvelder et al., 2007; Slemmer et al., 2000) and UCI-
30002 (Yamagata et al., 1993) are the synthetic non-competitive inhibitors of 
different nAChRs, including those made up of the subunits α7, α4β2, or α3β4. 
Even though there are excellent choice of natural and synthetic ligands that 
can mediate agonist or antagonist receptor activity, the utility of these ligands 
to distinguish between various nAChR subtypes still needs to be achieved. 
Therefore the knowledge regarding the physiology of nAChRs, the importance 
of diverse receptor subunit assembly and the functions mediated by them, their 
distribution in CNS and PNS, their association with various neurological 
disorders, is limited due to lack of subtype specific ligands for nAChRs. 
Therefore, the discovery and characterisation of new ligands with unique 
mode of ligand-receptor interaction and selectivity to nAChR subtypesfrom 
various unexploited sources are greatly necessary. These new leads can be 
further developed into pharmacological probes as well as research tools to 
dissect various physiological mechanisms associated with various subtypes of 
nAChRs. 
1.9 Antiquity of nAChRs: defined by predator-prey relationships 
The antiquity of a biological system and its necessity to survival go hand in 
hand with the number of organisms that use it as a target for defensive or 




system important for life and hence an excellent target system for predation or 
poisoning leading to a rapid host immobilization. There are numerous 
examples of such natural compounds devised by nature in course of evolution 
in order to target nAChRs. These Toxins are produced from extensive range of 
micro-organisms, plants and animals which are structurally different form 
each other. Despite their structural difference, they bind to the nAChRs at 
ligand-binding site to modify the receptor function (Figure 1.8). This indicates 
that these different toxins have coevolved with a recurrent convergent strategy 
to interact with nAChRs, driven by the interrelationship between predator-prey 
strategies (Reviewed in (Albuquerque et al., 2009). Probably because the 
origin of nAChR dates to the earliest of organisms and these receptors have 
acquired important roles in animal motility and nervous system function. 
Furthermore, the basic structure of the ligand binding site of nAChRs has been 
retained with remarkably little variability throughout evolution, making it an 
excellent structural target for a toxin (Reviewed in (Albuquerque et al., 
2009)).The focus of this thesis is on animal toxins, more specifically on snake 
venom toxins. As example, α-bungarotoxin, a historical toxin from the venom 
of Bungarus multicinctus snake, was proved to be a valuable toxin to 
researchers. As described in the earlier, discovery of α-bungarotoxin marked 
the major mile-stone both in snake venom research and in neurobiochemistry 
research by leading to the discovery and purification of the first nAChR. Since 
then, snake venom has been the one of the important natural sources of 
numerous toxins that targets nAChRs, with considerable receptor subtype 
specificity (For example; α-neurotoxins and κ- neurotoxins). Furthermore, 




that are structurally and functionally (mode of action and subtype selectivity) 
non-conventional compare to α- and κ- neurotoxins (Figure 1.6). 
 
Figure 1.12 Toxins that have coevolved to interact with nAChRs can be 
agonists or antagonists. Shown above are structural models of binding between 
nAChRs and a variety of toxins. Toxins are in red, the α-subunit is in dark blue, and the 
structural β subunit is in light blue. For α-cobratoxin, the protein surface was added to 
show the very tight fit between the toxin and the nAChR binding site. Several points are 
made. 1) The toxins come in a variety of forms. This includes the elaborate proteins 
produced in snake venoms to the simple molecules of plants used for defence against 
predation. 2) The toxins can function as either agonists or antagonists. 3) Note the 
interaction between toxin and receptor that is in general centred at the ligand bind ing site 
(note the yellow Cys-Cys pair that usually wraps the toxin at the site of ligand 
interaction). The exquisite refinement of toxin structure to bind the nAChR also 
indicates that this site in the nAChR has remained relatively invariant through its 
evolutionary history. The Figure 1.7 and its legend have been reproduced with the 
permission of Dr. E.X Albuquerque, Department of Pharmacology and 





This suggests that it is quite evident that these snake venom neurotoxins seem 
to have a considerable trend of evolving special ways within the three-finger 
fold to target nAChRs as predatory weapons and also as defensive measures 
and hence are interesting to exploit as research tools to study nAChRs 
1.10 Rationale and Aims 
1.10.1 Rationale: in the scope of nAChRs 
Nicotinic acetylcholine receptors mediate ionotropic actions of 
acetylcholine facilitating neurotransmission. However, due to the lack of 
highly selective ligands, the precise location, function and roles in various 
diseases of the nicotinic receptor subtypes still remain unclear. Meanwhile, the 
studies on neurotoxins isolated from snake venom have shown that they have a 
natural high affinity and selectivity to nAChRs, which act as competitive 
antagonists of nAChRs. The specificity of some neurotoxins is so exquisite 
that they are capable of discriminating subtle differences in binding site on a 
single receptor population, like the binding sites located at the interfaces of the 
α1/γ or α1/δ subunits in the muscle (α1)2β1γδ nAChR (Taylor P et al, 2002). 
These ligands of nAChRs are therefore promising for the development of 
therapeutic strategies for neurological disorders. Though there has been 
significant growth on nicotinic acetylcholine receptor research, our 
understanding of nAChRs is inadequate. For instance, there are still partially 
answered or unanswered imperative questions such as, whether the presence of 
various diverse nAChR subtypes is associated with diverse functional roles: Is 




underlying mechanism of selective activation or inactivation of a particular 
nAChR subtype? Likewise, it is crucial to understand the rules that govern the 
assembly of nAChR subunits into functional receptor subtypes and how these 
functional receptor subtypes distributed or compartmentalized to definite cell 
types in the body. Therefore, the development of new and unique ligands that 
have higher selectivity and specificity to diverse nAChR subtypes might 
become a necessary research tool to answer many of these questions and hence 
is necessary.  
1.10.2 Rationale: in the scope of snake venom research 
Even though the early snake venom research was fueled by the motivation 
to find satisfactory means to neutralize the toxicity and adverse effects of 
snake envenomation, perspectives on snake venom research has taken leaps 
over the years with the extensive study of snake venom components. These 
biomolecules have assumed great significance as molecular probes and 
pharmacological tools to investigate the functional biology of receptors and 
ion channels as well as providing lead compounds for the design of clinically 
useful drugs (McCleary and Kini, 2013). Despite much research, there are 
only a handful of the venom components that have been fully understood, for 
example; 20 different clades of “orphan toxins” identified from snake venoms, 
whose function is not yet known (As discussed in the section of neurotoxins) 
and there are still un-explored arenas of snake venom components such as the 
inherent evolutionary complexity observed in many toxin families which have 




compact and similar structural mould, for instance,candoxin form Bungarus 
candidus venom, unlike short- and long-chain α- neurotoxins candoxin is 
structurally distinct with a 5
th
 disulphide bridge in loop-I and also has non-
conventional functional array (Nirthanan et al., 2002) and haditoxin form 
Ophiphagus hannah venom, which unlike α- and κ- neurotoxins exists as a 
non-covalent dimer at the physiological pH and also has a different selectivity 
profile on nAChR subtypes (Roy et al., 2010). The presence of such large 
number of orphan toxins in the growing toxin family, suggests that there are 
still many 3FTx with unique and new pharmacological potencies, which are 
yet to be discovered and characterized. 
1.10.3 Aims: specific aims 
This brings us to the main objective of the thesis, the structural and 
functional characterization of Oh9-1 and exactin, novel and unique 3FTxs 
from snake venom.  
Oh9-1, isolated from the venom of Ophiophagus hannah, comprises of 57 
amino acids residues, lacks most of the critical residues that are reported to be 
crucial for the α-neurotoxins to bind and antagonize nAChRs with high 
affinity (Pillet, Menez et al., 1993) (Antil et al., 1999).  Despite this, Oh9-1 is 
just four fold less potent than the most potent α-bungarotoxin on Chick neuro-
muscular junction (Long-Sen Chang, et al, 2002). This indicates that Oh9-1 is 
probably interacting with nAChRs either at a completely different site 
(allosteric-site) than α-neurotoxins or at a same site with completely distinct 




discovery of nAChR ligands which can be potential allosteric modulators and 
orthosteric ligands with unique mode of action is of high therapeutic and 
research interest in the field of neurobiology. Therefore, understanding the 
structure-function relationships of Oh9-1 and delineating its functional site 
thatinteracts with nAChRs is of imperative interest. 
Exactin, isolated from Hemachatus haemachatus venom also has 57 amino 
acid residues. Exactin shares identical loop-II with Oh9-1 and due to this, 
exactin also lacks all the previously mentioned critically important residues to 
bind to nAChRs (Pillet, Menez et al., 1993) (Nirthanan Matthew C.E. Gwee., 
2004). However, exactin was previously characterized as a novel three-finger 
toxin with a dual function; (i) a potent and specific anticoagulant effect on the 
FX activation by the complete extrinsic tenase complex and (i) a weak, and 
reversible, postsynaptic neurotoxicity effect on Chick neuro-muscular junction 
(VM Girish, PhD thesis, National University of Singapore, 2012).Therefore, it 
would be interesting to further characterise the neurotoxic property of exactin. 
Various molecular biology, pharmacology and structural biology 
approaches have been employed in the course of characterization of Oh9-1 and 
exactin. They are described under following specific objectives; 
 Detailed functional and structural characterisation of recombinant 
Oh9-1 
1. Cloning, recombinant expression, refolding and purification of 




2. Pharmacological characterization of Oh9-1 on isolated chick nerve-
skeletal muscle preparations. 
3. Electrophysiological studies of Oh9-1 on ACh evoked currents in 
various subtypes of muscle and neuronal nAChRs expressed in 
Xenopus oocytes. 
a) Determining the nAChR subtype selectivity of Oh9-1 
b) Determining the IC50 concentrations of Oh9-1 on nAChR 
subtypes based on their subtype selectivity profile. 
c) Investigating the mode of binding of Oh9-1 with nAChR  
d) Determining the cross-reactivity of Oh9-1 with other Cys-loop 
receptors than nAChRs. 
4. Investigating the interaction of Oh9-1 with AChBP through radio-
ligand binding assay  
5. Determining the three-dimensional structure of Oh9-1  
 
 Delineation of the functional site of Oh9-1 through alanine scanning 
mutagenesis 
1. Recombinant expression, refolding and purification of alanine 




2. Screening Oh9-1 alanine mutants on selective nAChR subtypes 
based on their subtype selectivity profile of wild-type Oh9-1. 
 
 
 Interaction of exactin (a paralogue of Oh9-1) with nAChRs 
1. Isolation and purification to homogeneity of exactin from crude 
Hemachatus haemachatus venom. 
2. Electrophysiological studies of exactin on ACh evoked currents 
in various subtypes of muscle and neuronal nAChRs expressed 
in Xenopus oocytes. 
a) Determining the nAChR subtype selectivity of exactin 
e) Determining the IC50 concentrations of exactin on nAChR 
subtypes based on their subtype selectivity profile. 
 Evolution of Ω-neurotoxins 
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Oh9-1, isolated from the venom of Ophiophagus hannah, comprises of 57 
amino acids residues, which is shorter than the type-I (short-chain) α-
neurotoxins. Sequence alignment of Oh9-1 with the well characterized 
canonical short-chain α-neurotoxin, erabutoxin-b (Eb-b), showed that Oh9-1 
has a much shorter loop-I (5 residue shorter) and loop-III (3 residue shorter), 
whereas a residue longer loop-II in comparison with Eb-B (Figure 2.0). In 




































/_(erabutoxin a/α-cobratoxin numbering), that are 
reported to be crucial for the α-neurotoxins to bind and antagonize nAChRs 
with high affinity (Pillet, Menez et al., 1993) (Antil et al., 1999).  Despite this, 
Oh9-1 is just four fold less potent than the most potent α-bungarotoxin on 
Chick neuro-muscular junction (Long-Sen Chang, et al, 2002). These 
observations clearly indicated that Oh9-1, even though it belongs to 3FTx 
family, has prominent structural differences (much shorter loops –I, -III and a 
residue longer loop-II and complete replacement of functional site described in 
α-neurotoxins) and yet exhibits similar function of antagonizing nAChRs. 
Usually the structure and function of protein are highly correlated, where the 
interaction of proteins, via specific molecular recognition site with their target 
proteins leads to the execution of specific biological functions. Irrespective of 
the complexity in size, structure and conformation of the proteins, the 
molecular recognition sites are usually compact and well defined, facilitating 







Figure 2.0 Comparison between the amino acid sequences of Oh9-1 and other three-finger toxins from snake venom. Sequence 
alignment of Oh9-1 with (A) the most homologous 3FTx sequences, and (B) canonical short-chain α-neurotoxins. Toxin names, species and accession numbers 
(ACCN) are shown. Disulphide bridges and loop regions are also shown. The number of amino acid residues and homology (sequenc e identity (%Id)) to Oh9-1 of 
each protein is shown at the end of sequences. Amino acid residues that are critical for interacting with nAChR in canonical short -chain α-neurotoxins are 
highlighted in grey. Asterisks indicate that OH5 (He et al., 2004) and SNTX11 (Li et al., 2006) have an identical mature protein sequence, but a single residue 




Organism ACCN Amino acid sequence  %Id 
A 
          Loop I                              Loop II                              Loop III   
Oh9-1  O. hannah       P83302 LICHRVHGLQTCEPDQKFCFRKTTMFFPNHPVLLMGCTSSCPTEKYSV-CCSTDKCNK 57  
SNTX11   O. hannah       Q2VBP1 LICHRVHGLQTCEPDQKFCFRKTTMFFPNHPVLLMGCTYSCPTEKYSV-CCSTDKCNK 57 98 
Oh-5  O. hannah       Q53B47 LICHRVHGLQTCEPDQKFCFRKTTMFFPNHPVLLMGCTYSCPTEKYSV-CCSTDKCNK 57 98 
SNTX26  O. hannah       Q2VBN9 LICHQVHGLQTCEPAQKFCQKRTTMFFPNHPVLLMGCTYNCPTERYSV-CCSTDKCNK 57 86 
SNTX14 O. hannah       Q2VBP0 LICHQLHGLQTCEPAQKFCQKRTTMFFPNHPVLLMGCTYNCPTERYSV-CCSTDKCNK 57 86 
Oh-46  O. hannah       Q53B48 LICHQVHGLQTCEPAQKFCQIRTTMFFPNHPVLLMGCTYNCPTERYSV-CCSTDKCNK 57 84 
SNTX6  O. hannah  Q2VBP2 LICHQLHGLQTCEPAQKFCQKRTTMFSPNHPVLLMGCTYNCPTERYSV-CCSTDKCNK 57 82 
Oh-26 O. hannah       Q53B52 LICHQRHGLQTCEPAQKFCFAQTVMPFPNHPLTLMGCTYSCPTEKNAV-CCSTDKCNR 57 79 
Oh-32   O. hannah       Q53B50 LICNRVHGLQTCEPAHKFCFSKTVMPFPNHPLTLMGCTYSCPTERNAV-CCSTDKCN- 56 77 
CM-1b H. hemachatus   P01402 LECYQKSKVVTCQPEQKFCYSDTMTFFPNHPVYLSGCTF-CRTDESGERCCTTDRCNK 57 51 
Mamb-1  
  








        Loop I                                       Loop II                                      Loop III   
Oh9-1  O. hannah       P83302 LICHRVH-GLQ--T---CEPDQ-KFCFRKTTMFFPNHP-VLL-MGCTSSCPTEK-YSV---CCSTDKCNK 57  
Eb-B L. semifasciata 1ERA RICFN-HQSSQPQTTKTCSPGESS-CYHK--QW-SDFRGTIIERGC-G-CPTVKP-GIKLSCCESEVCNN 62 32 

















This understanding and analysis suggests that Oh9-1 is a novel and unique 
3FTx whose structural and functional characterization could reveal novel 
modes of ligand-receptor interaction. For instance, Oh9-1 with those structural 
differences may interact with nAChRs at either a completely different 
interacting site (allosteric-site) than α-neurotoxins or at a same site with 
completely distinct functional site than α-neurotoxins. Therefore, it was 
interesting for us to understand the structure-function relationships of Oh9-1 
and delineating its functional site interacting with nAChRs. 
Even though there were reports of isolation of Oh9-1 from the venom of 
Ophiophagus hannah, recombinant expression of Oh9-1 was employed, in 
order to facilitate further mutational studies in its detailed characterization. In 
addition, Oh9-1 was not found in large quantities from the venom and also not 
found in all the king cobra venoms from various geographical locations. This 
chapter details the description of cloning, recombinant expression, refolding, 
purification and subsequent functional and structural characterization of a 
novel three-finger neurotoxin, Oh9-1. 
2.2 Materials and Methods 
2.2.1 Materials  
The gene encoding wild type Oh9-1 was custom synthesized from DNA 2.0 
(Menlo Park, CA, USA) with codon optimization for over-expression in E. 
coli. Kapa High Fidelity PCR kits were purchased from Kapa Biosystems 
(Wilmington, MA, USA) and DNA ladders were purchased from Invitrogen 
(Grand Island, NY, USA). Custom oligonucleotides were from 1st Base Pte. 
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Ltd., Singapore. Luria-Bertani broth and agar were purchased from 
Q.BIOgene (Irvine, CA, USA). Restriction endonucleases (Fast digest) and 
Rapid DNA ligation kit were purchased from Fermentas International Inc. 
(Waltham, MA, USA). SHuffle® T7 Express lysY competent E. coli were 
obtained from New England Biolabs (Beverly, MA, USA). PAGE Precision 
Plus Protein™ Dual-Colour Standards (marker for SDS-PAGE) were 
purchased from Bio-Rad (Hercules, CA, USA). Acetonitrile (ACN) and 
trifluoroacetic acid (TFA) solvents were purchased from Merck KGaA 
(Darmstadt, Germany). The drugs used in organ bath experiments; 
acetylcholine (ACh) and carbachol (CCh) were purchased from Sigma Aldrich 
(St. Louis, MO, USA) and α-bungarotoxin and ETxb were purchased from 
Latoxan (Valence, France). Crystal screening solution and accessories were 
obtained from Hampton Research (Aliso Viejo, CA, USA). The PACT Suite 
for crystallization was purchased from QIAgen (Hilden, Germany). Superdex 
75 column (1 cm x 30 cm) and Jupiter C18 (5 μ, 300 Å, 4.6 mm x 150 mm) 
columns were purchased from GE Healthcare Life Sciences (Piscataway, NJ, 
USA) and Phenomenex (Torrance, CA, USA), respectively. The protein 
markers used for gel filtration studies were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). All the chemicals and reagents used were of analytical 







Locally-bred domestic chicks (Gallus gallus domesticus) were purchased from 
Chew’s Agricultural Pte Ltd (Singapore) and delivered on the day of 
experimentation. All animals were sacrificed by exposure to 100% carbon 
dioxide before isolation of the respective tissues. All Chick experiments were 
conducted in accordance to the protocol 103/08A approved by the Institutional 
Animal Care and Use Committee (IACUC) of the National University of 
Singapore.  
2.2.3 Methods 
Cloning of Oh9-1 gene into pET-22b vector 
The 186 bp synthetic gene was received in pJE- expression vector. The 
optimized gene sequence and the cloning strategies are illustrated in Figure 2.1 
and 2.2 respectively. The synthesized DNA was amplified by PCR using 
forward primer (5’-TATCATATGTTAATCTGTCATCGTGTC-3’) and 
reverse primer (5’-TATGGATCCTTACTTGTTGCATTT-3’) having NdeI 
and BamHI restriction sites respectively. Three extra nucleotides were added 
at 5’ end of each primer to facilitate subsequent digestion by restriction 
endonucleases. The PCR mixture contained 1 μl of 1:10 diluted recombinant 
pJE-vector, 1 unit of kappa HiFi Polymerase, 1 μl of 10 mM of each primer, 1 
μl of 10 mM dNTPs, 5 μl of 10X kapa HiFi PCR buffer in a total volume of 50 
μl. The PCR conditions were as follows: one cycle of 95ºC for 2 min, 35 
cycles of 98ºC for 20 s, 59ºC for 15 s and 72ºC for 15s, and a final extension at 
72ºC for 5 min. After PCR, the amplified product was run on 1% (w/v) 
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agarose gel followed by gel extraction. Both, the amplified PCR product as 
well as pET-22b was doubly digested with NdeI and BamHI. Normally, the 
double digestion mixture consisted of ~1000 ng of vector or insert, 1 μl each 
enzyme, 2 μl 10X buffer and total volume was raised to 20 μl each with 
autoclaved water followed by incubation at 37°C for 1 h. The digested 
products were run on 1% (w/v) agarose gel followed by gel extraction. The 
ligation mixture contained 1:1 molar ratio of insert to vector, 1 μl of T4 DNA 
fast ligase, 2 μl of 5X ligation buffer and total volume was raised to 20 μl with 
autoclaved water. The ligation reaction was incubated at 22°C for 2 hours.  
Transformation of clone and expression host strains 
The ligation mix was used to transform E. coli DH5α competent cells 
(cloning hosts) by heat-shock transformation protocol as follows; a vial of 50 
μl competent cells was allowed to thaw on ice for 15 min. Then, 5 μl of 
incubated ligation mixture or 1 μl of recombinant plasmid was added to 
competent cells and placed back on ice for 30 min. The cells were incubated 
for 90 s at 42°C and immediately kept on ice for 5 min. Subsequently, 200 μl 
of LB broth was added to the cells and incubated at 37°C for 1 h with shaking 
at 400 g. Then the cells were plated onto LB agar plates containing 100 μg/ml 
ampicillin and incubated overnight at 37°C 
Plasmid DNA isolation 
The plasmids were isolated from positive transformants as follows; the 
plates were removed after 16 h of incubation at 37ºC to avoid overgrowth. 
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Each selected colony was separately inoculated in 2 ml LB broth 
supplemented with 100 μg/ml ampicillin and incubated at 37°C with shaking 
at 400 g for 16 h. Plasmid DNA was isolated using GeneAll™ plasmid 
preparation kit using the protocol recommended by the manufacturer. 
Concentration and purity of DNA were measured using the NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies) and recorded using the 
supplied software ND-1000 V3.3.0. 
DNA sequencing and analysis 
The fidelity of the recombinant plasmid was confirmed by sequencing with 
primers specific for T7 promoter and T7 terminator sequences as follows; the 
nucleotide sequence of the gene was determined by ABI PRISM® Big 
Dye™Terminator Cycle Sequencing Ready Reaction Kit (version 3.0) (PE-
Applied Biosystems, CA, USA). Each sequencing reaction was prepared by 
mixing 100 ng of recombinant plasmid DNA, 2 μl Big Dye and 1 μM of T7 
promoter or T7 terminator primer in a total volume of 5 μl reactions. The PCR 
conditions were as follows: 96ºC for 1 min, 25cycles of denaturation at 96ºC 
for 10 s, annealing at 50ºC for 5 s and extension at60ºC for 2 min. The PCR 
amplified products were purified with CleanSEQ magnetic beads as 
recommended by the manufacturer. The purified DNA were eluted in 
autoclaved water and loaded on an automated ABI PRISM® 3130XL Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA). Analysis of the 
sequence data was carried out using Chromas 2 and Gene Runner software. 
Then the positive recombinant plasmids were used to transform expression 
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hosts. 1 μl of the plasmid was used to transform the expression hosts (in this 
case NEB SHuffle Lys Y cells). After shaking at 37 °C, the cells were plated 
(100 μl each plate) on LB agar medium supplemented with 100 μg/ml 
ampicillin (Amp).  
Protein expression 
 A single colony harbouring recombinant vector was used for inoculation of 
2 ml of LB medium containing 100 μg/ml of antibiotic and incubated at 37 °C 
with shaking at 400 g overnight (up to 16 hours). The overnight grown, starter 
culture was inoculated into 250 ml †culture flask containing 50 ml of fresh LB 
medium (supplemented with appropriate amount of antibiotic) at a dilution of 
1:50. The flask with the bacterial culture was incubated at 37 °C and 400 g 
until the culture reached an A600 of approximately 0.6-0.8, which took 
approximately 4 to 5 hours. At this stage, the glycerol stocks were made by 
aliquoting 750 μl of the culture into a 1.5 ml eppendorf tube containing 250 μl 
of 80% glycerol followed by snap freezing in the liquid nitrogen and kept at -
80 °C until further use. Also, an aliquot (1 ml) was kept aside as un-induced 
control. The remaining culture was induced by the addition of IPTG stock to 
achieve a desired concentration in the total volume of the culture and 
incubated at desired temperature. The cultures of SHuffle cells harbouring 
pET-22b were induced with 1 mM IPTG and incubated at 37°C for 4 hours or 
16ºC for about 18-20 hours. After the respective incubation periods of induced 
cultures, again 1 ml aliquot was kept aside as induced control. The expression 
of recombinant protein in E. coli was analysed by Tris-tricine gel for optimal 
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expression conditions (Table A.2 in Appendix). Later the optimized 
expression conditions were scaled up for large scale (1L culture) expression of 
the protein. On completion of the induction time, the cells were harvested by 
centrifuging the cultures at 12,000 g for 30 min at 4°C. The cells were washed 
once with MilliQ water, drained completely and then the cell pellets were 
stored at -80°C until further use. The expression of recombinant protein was 
analysed by SDS-PAGE on a 15% tris-tricine SDS-polyacrylamide gel. 
Preparation and solubilisation of inclusion bodies from expressed cells 
Bacterial cell pellets were thawed on ice and then was resuspended in cold 
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0) by vortexing the 
solution. The ratio of cold lysis buffer to culture volume is dependent on the 
expression yield (in this case, 250 ml of lysis buffer was used per litre cell 
pellet). The solution was subjected to ultrasonication (Pulse frequency: 1 s on 
and 1 s off) for about 20 min in the parts of per 50 ml of resuspended cell 
pellet, until the solution was clear and non-viscous and then centrifuged again. 
During sonication, the solution was adequately cooled by placing the tube in 
an ice-box. The solution was centrifuged at 12,000 g for 30 min at 
4°C.Subsequently, the supernatant was transferred to a new tube without 
disturbing the pellet. The insoluble pellet fraction was stored at -80°C until 
further use. 
For the preparation of pure inclusion bodies, the insoluble pellet was 
resuspended lysis buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0) with 1 % 
Triton X-100 and the solution was kept on shaking at 4°C. This should 
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solubilise membranes and membrane proteins. The better the resuspension of 
the insoluble pellet, the better the result will be in the end. A short sonication 
of pulse frequency 1s ON and 1s OFF of about 8 min is employed and the 
solution is centrifuged at 12,000 g for 30 min. The insoluble pellet obtained is 
again subjected to sonication, followed by centrifugation in 1% Trition X-100 
containing lysis buffer as described above until the supernatant obtained after 
centrifugation is completely clear and colourless. This indicates that obtained 
insoluble pellet after wash steps is the pure inclusion bodies devoid of all the 
cell debris. The quality of inclusion bodies prepared is further analysed by 
SDS-PAGE. 
For extracting the protein from prepared inclusion bodies, the insoluble 
pellet was resuspended in denaturing buffer (6 M Guanidine hydrochloride 
(GnHCl), 50 mM Tris-HCl, 50 mM NaCl, pH 8.0) and the solution was kept 
on shaking at room temperature. After overnight solubilisation of pellet in the 
denaturing buffer, the solution was centrifuged at 14,000 g for 30 min at 4°C 
to obtain the solubilised inclusion bodies. 
Preparing samples for PAGE 
The aliquots (1000 μl) of uninduced and induced cultures were spun at 
3,000 RCF for 15 min at room temperature (RT) and washed with water. Also, 
the pellet after lysis and inclusion body preparation wash steps were washed 
with water. The pellets were suspended in 300 μl of 8M Urea buffer (8M Urea, 
50 mM Tris.Cl, pH = 8.0 with freshly added 50 mM DTT) and spun at 3,000 
RCF for 10 min. A supernatant sample from each aliquot (15 μl) was mixed 
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with 5 μl of 5X sample loading dye (Table A.3 in Appendix). Final sample 
from inclusion body preparation solubilized under denaturing conditions using 
6M GnHCl were subjected to Trichloroacetic acid (TCA) precipitation, to get 
rid of the salts that may interfere while running on gel. TCA precipitation; 
briefly, 1:1::sample:10% TCA were mixed and incubated on ice for 30 min 
followed by centrifugation at 9,000 RCF for 10 min at 4 °C. The pellets were 
washed with ice cold 100% ethanol twice and air dried. The final pellet was 
suspended in 300 μl of PBS and 15 μl aliquot from the same was mixed with 5 
μl of 5X sample loading dye as stated above. All the samples with loading dye 
were incubated at 100°C for 10 min and spun at 3,000 RCF for 10 min at room 
temperature before loading on to Tris-Tricine gel. 
Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) 
Bio-Rad Mini-PROTEAN™ gel system was used to run SDS-PAGE. The 
12% or15% polyacrylamide gels were casted as indicated in Appendix (Table 
A.1). Samples were prepared by mixing 15 μl of the sample with 5 μl of 5x 
loading dye andsubsequently boiled for 10 min. After spinning it in a micro 
centrifuge, 15 μl was loaded on to the gel. For the molecular weight ladder, 5 
μl of Precision plus protein dual Xtra standards was run in one lane. 
Electrophoresis was carried out at 120 V until the visible marker reached near 
the end of the gel. The gel was stained with SimplyBlue™SafeStain. 
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Reduction of solubilised inclusion bodies 
The denaturing agents such as Urea and GnHCl used, only disrupts 
secondary/tertiary structure of the protein but does not reduce the protein. 
Therefore, the solubilized inclusion bodies under denatured conditions were 
reduced with the addition of 2 % DTT. The mixture was incubated at RT for at 
least 1 h, in order to reduce any possible soluble intermolecular and intra-
molecular disulphide bridge formations. 
Protein purification on RP-HPLC 
The reduced inclusion body preparation was filtered with 0.4 micron 
syringe filters, before purification on RP-HPLC column attached to AKTA 
purifier system (GE Healthcare Life Sciences, Piscataway, NJ, USA). The 
filtrates were injected into Jupiter C18 column pre-equilibrated with buffer A 
(0.1% (v/v) Trifluoroacetic acid; TFA in water). The reduced protein was 
eluted with a linear gradient of32%-42% of buffer B (80% acetonitrile (v/v) in 
0.1% (v/v) TFA) for over a period of 100 min at flow rate of 2 ml/min (Flow 
rates of analytical column is 1ml/min; 2 ml/min for semi-preparative column 
and 5 ml/min for preparative column). The elution was monitored at 215 nm, 
254 nm and 280 nm. 
Molecular mass determination 
The molecular mass and homogeneity of the fractions of interest eluted was 
determined by electrospray ionization mass spectrometry (ESI-MS). Fractions 
of interest were directly injected to LCQ Fleet™ Ion Trap Mass Spectrometer 
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(Thermo Fisher Scientific, USA). Data was acquired in positive ion mode. 
ACCELA-600 pump was used for solvent delivery (50% (v/v) acetonitrile 
in0.1% (v/v) formic acid) at a flow rate of 100 μl/min. Full scan data were 
acquired over the range from 500 to 2000 m/z with step mass of 0.1 Da. 
ProMass Deconvolution™ Software was used to analyse and deconvolute the 
raw mass data. Fractions showing the expected reduced molecular mass were 
lyophilized. 
Refolding of protein 
The refolding of reduced protein was tried both from reduced inclusion 
bodies directly and from the reduced lyophilised powder.  
Refolding from inclusion bodies; the inclusion body pellet after wash steps 
was dissolved in 1ml of mild denaturing buffer (3 M GnHCl, 10 mM EDTA, 
20 mM Tris.Cl, pH 8.0) and reduced with 10 mM DTT for 1 hour at 37ºC. 
After reduction, the solution was centrifuged at 5,000 RCF for 10 min and 
supernatant was diluted with mild denaturing buffer for a final concentration 
of ~10 μM and was dialysed against 2L of refolding buffer (0.425 M GnHCl, 
20mM NaCl, 1 mM reduced glutathione, 1 mM oxidized glutathione, 1 mM 
EDTA, 50 mM Tris.Cl, pH 8.0 and 10% glycerol) for 2–3 days at 4ºC. After 3 
days of dialysis, to stop the redox reactions by acidification, TFA was added to 
the dialysed sample such that the final concentration becomes 1% TFA, and 




Refolding from lyophilised powder; the lyophilized powder of fractions 
pooled from RP-HPLC of Oh9-1 was dissolved in mild denaturing buffer (3 M 
GnHCl, 10 mM EDTA, 20 mM Tris.Cl, pH 8.0) to a final concentration of ~10 
μM and reduced with 10 mM DTT for 1 hour at 37ºC.The reduced protein was 
then dialyzed for 3 days against the refolding buffer (0.425 M GnHCl, 20mM 
NaCl, 1 mM reduced glutathione, 1 mM oxidized glutathione,1 mMEDTA, 50 
mM Tris.Cl , pH 8.0 and 10% glycerol)at 4ºC. After 3 days of dialysis, the 
refolding reaction was stopped by acidification with TFA such that the pH of 
the solution was maintained at pH3-pH 5 and further centrifuged at 8,000 RCF 
for 30 min at 4ºC to remove any possible precipitates.  
The dialysed sample was then filtered and purified on RP-HPLC and eluted 
with a linear gradient of eluted with a linear gradient of 22–40% of solvent B 
over a time period of 60 min at a flow rate of 1 ml/min on Jupiter C18 (5 μ, 
300 Å, 4.6 mm×250 mm) analytical column. The molecular weight of the 
refolded protein fractions were determined by LCQ Fleet™ Ion Trap Mass 
Spectrometer system as mentioned above. After analysing the mass and 
homogeneity by ESI-MS, the protein fractions eluted in the major peak were 
pooled and lyophilized.  
Gel filtration chromatography 
The oligomeric states of the protein were examined by gel filtration 
chromatography on a Superdex 75 column (1 cm x 30 cm) equilibrated with 
50 mM Ammonium bicarbonate buffer (pH 7.4) using an ÄKTA purifier 
system at a flow rate of 1 ml/min. Calibration was done using bovine serum 
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albumin (66 kDa), carbonic anhydrase (29 kDa), cytochrome C (12.4 kDa), 
aprotinin (6.5 kDa) and bluedextran (200 kDa) as molecular weight markers. 
Purified and refolded Oh9-1 (0.25-10 μM) were loaded onto the column and 
elution profiles were recorded. 
Circular dichroism (CD) spectroscopy 
Far-UV CD spectra (260-190 nm) were recorded using a Jasco J-810 
spectropolarimeter (Jasco Corporation, Tokyo, Japan) as described previously 
(Rajagopalan et al., 2007). The refolded protein sample (concentration 20μ M) 
was dissolved in MilliQ water and placed in a cuvette with 0.1 cm path length. 
The cuvette chamber and instrument optics were continuously purged with 
nitrogen before and during the recording of the spectra to provide an oxygen-
free environment. The spectra were recorded using a scanning speed of 50 
nm/min, a data pitch of 0.1 nm and a bandwidth of 1 nm. An average of three 
scans was taken to increase the signal to noise ratio and the baseline was 
subtracted with the blank. The α-helix, β-sheet, and random coil content were 
estimated using the method described at http://www.embl.de/~andrade/k2d/. 
Ex vivo organ bath experiment using isolated CBCM  
Isolated tissue experiments were conducted using a conventional organ bath 
(6 ml) containing physiological Krebs-Henseleit buffer of the following 
composition (in mM): NaCl (118), KCl (4.8), KH2PO4 (1.2), CaCl2 (2.5), 
MgSO4 (2.4), NaHCO3 (25) and D-(+) glucose (11), pH 7.4. The buffer 
solution was prepared in de-ionized water and continuously aerated with 
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carbogen (5% carbon dioxide in oxygen). The temperature of the organ bath 
was maintained at 37°C throughout the experiment. Three to five day old 
chicks were sacrificed by exposure to 100% CO2 and the chick biventer 
cervicis muscle (CBCM) was isolated by making a midline incision down the 
back of the animal’s neck exposing a pair of biventer cervicis muscle on either 
side of the midline. The muscles were removed and each was attached to a tissue 
holder with the platinum ring electrodes positioned around the tendon. Isolated 
CBCM tissues were mounted in the organ bath chamber under a resting 
tension of ~1 g as the magnitude of the contractile response was measured in 
gram (g) tension. Tissue preparations were allowed to equilibrate for 30 - 45 
min with changes of Krebs solution at 15 min intervals before the 
commencement of an experiment. Electrical field stimulation (EFS) was 
provided through platinum ring electrodes using a Grass stimulator S88 (Grass 
Instruments, West Warwick, RI, USA).Maximal twitch responses of the 
muscle were evoked by stimulating the motor nerve by EFS (7 V) at a 
frequency of 0.2 Hz in supramaximal rectangular pulses of 0.1 ms duration. 
For direct muscle stimulation, the electrodes were lowered over the belly of 
the muscle and twitch responses were evoked by EFS (20-30 V, 0.2 Hz, 1 ms). 
The data was continuously recorded on Power Lab/Chart 5 data acquisition 
system via a force displacement transducer (Model MLT0201) (AD 
Instruments, Bella Vista, NSW, Australia). The neuromuscular blockade 
produced by the toxin was expressed as a percentage of the original twitch 
height before exposure to the toxin. Submaximal contractures to exogenously 
applied agonists ACh (100 μM), CCh (20 μM) or KCl (30 mM) with contact 
time 30, 60 and 90 s, respectively were obtained in the absence of EFS.  
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The effects of Oh9-1on the uninterrupted twitch responses of the CBCM to 
nerve or direct muscle stimulation is then examined. Each preparation was 
exposed to one concentration of the test substance. The effects of Oh9-1on the 
responses of the CBCM to exogenous ACh, CCh or KCl were investigated 
immediately after complete blockade of nerve-evoked twitch responses were 
established. In separate experiments, the reversibility of the inhibitory effect of 
the toxins on the twitches was assessed by thoroughly washing muscle 
preparation with Krebs solution; at regular cycles of 30 s wash followed by 1 
min interval over a period of 30 min after at least 80% of the blockade had 
taken place. Dose response curve of Oh9-1 after 30 min of exposure to the 
toxin at each dose was plotted using GraphPad Prism 6 (La Jolla, CA, U.S.A.). 
The time taken to block the amplitude of control twitch responses by 80% 
(T80) was also plotted to measure the neurotoxicity quantitatively. 
The CBCM is a pair of muscles located at the back of the animal’s neck and 
each muscle is associated with a tendon where the nerve supplying the muscle 
is located (Figure 2.1A). The CBCM contains two types of muscle fibres, fast-
twitch muscle fibres and slow muscle fibres. The fast-twitch muscle fibres are 
focally innervated and can be activated by electrical field stimulation (EFS) of 
the motor nerve inside the tendon, producing nerve-evoked twitch responses. 
The slow muscle fibres are multiply-innervated, and while they do not have a 
propagated action potential, they can be stimulated by the addition of 
exogenous agonists such as ACh, carbamylcholine chloride (CCh) and 
potassium chloride (KCl) to give a sustained contracture (Toutant et al., 1981). 
Due to the presence of these two types of muscle fibres, it is possible to 
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distinguish between presynaptic neurotoxins and postsynaptic neurotoxins 
(Harvey Rowan et al., 1989; Geh et al., 1992; Harvey et al., 1994). For 
instance, venoms and toxins can cause neurotransmission blockade via a pre-
junctional mechanism by interfering with the release of neurotransmitters, or 
via a post-junctional mechanism by directly inhibiting the nAChRs located on 
the postsynaptic motor-endplate. Hence, a presynaptically acting neurotoxin 
would abolish nerve-evoked twitch responses without affecting the contractile 
responses to exogenously applied agonists. On the other hand, a 
postsynaptically-acting neurotoxin will abolish both nerve-evoked twitch 
responses as well as agonist-induced contractile responses in the muscle 
(Ginsborg and Warriner, 1960; Harvey, 1994) (Figure 2.1B). In addition, the 
CBCM can also be used to assess myotoxicity of venoms and toxins. 
Myotoxicity in the muscle is characterized by a slowly developing contraction 
of the muscle, inhibition of muscle response to exogenously applied KCl and 





Figure 2.1 Schematic showing different steps of ex vivo assay. (A) Dissection of 
CBCM from the dorsal side of the chick. (B)CBCM mounted on the organ bath chamber 
(C) The transducer on top of organ bath transmits the electronic signals and the 
converted digital data can be seen on the computer screen. (D) A segment of trace 
showing a control experiment in which only PBS is added to the CBCM preparation. 
Figure 2.1 has been reproduced form Shifali Chatrath, Ph.D thesis, NUS, 2010. 
 
Figure 2.2 Determination of the mode of neuromuscular blockade in the avian 
NMJ. Segments of organ bath tracing showing neuromuscular blockade in isolated 
CBCM produced by (A) a postsynaptic neurotoxin and (B) a presynaptic neurotoxin. 
Figure 2.2 has been reproduced from Foo Chun Shin, Ph.D thesis, NUS, 2010. 
However, this will only provide pharmacological evidence of myotoxicity and 
histopathological examination of the muscle structure should be conducted to 
confirm the myotoxic effects of the venoms or toxins. The reversibility of 
neurotoxic activity of the venoms and toxins can also be assessed by repeated 
washing of the tissue preparations. Due to the robustness of this preparation 
and the ease of dissection, the CBCM is a useful preparation to screen for 




Stage V-VI oocytes were harvested from anaesthetized (with 0.1% 
Tricaine) mature female Xenopus laevis, following the protocols approved by 
the RMIT Animal Ethics committee. 
To perform two-electrode voltage-clamp (TEVC) experiments on Xenopus 
oocytes, RNA of nAChR subunits were prepared and microinjected into 
oocytes for nAChR subtype expression. Briefly, cDNA encoding the human 
and rat α3, α4, α9, α10, α7,  β2 and β4 subunits, and rat α1, β1, γ, δ and ε 
subunits, sub-cloned into the oocyte expression vector pT7Ts were used for 
mRNA preparation using the mMESSAGE mMACHINE kit (Ambion®, Life 
Technologies Australia Pte. Ltd., Mulgrave, VIC, Australia). 25 ng of cRNA 
was microinjected into oocytes, then kept at 18ºC in ND96 buffer (96 mM 
NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 7.4) supplemented 
with 50 mg/l gentamicin and 100 μg/units/ml penicillin-streptomycin for 2-5 
days before recording. The oocytes were clamped using a GeneClamp 500B 
amplifier (Molecular devices, Sunnyvale, CA, USA). Voltage recording and 
current-injecting electrodes were pulled from borosilicate glass (GC150T-7.5, 
Harvard Apparatus Ltd., Holliston, MA, USA) and had resistances of 0.3-1.5 
MΩ when filled with 3 M KCl. 
All TEVC recordings were made at room temperature (20-23ºC), using a 
bath solution of ND96. The oocytes were continuously perfused at a flow rate 
of 2 ml/min with ND96 buffer during recordings, with toxin incubated for 5 
min before ACh was added. ACh of definite concentration (determined EC50 
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concentration for each nAChR subtype) was applied for 2 s at 2 ml/min, with 5 
min washout periods between applications. Oocytes were voltage clamped at a 
holding potential of -80 mV. Data were filtered at 10 Hz and sampled at 500 
Hz. 
Data analysis - Concentration response curves for antagonists were fitted by 
unweighted nonlinear regression to the logistic equation:  
Y = Bottom + (Top – Bottom)/ (1+10 ^ ((Log IC50 – X)*Hill Slope)), where Y 
is the normalised response, X is the antagonist concentration, Top and Bottom 
are maximal and minimal normalised responses, respectively, and IC50 is the 
antagonist concentration giving 50% inhibition of the maximal response.  
The Schild EC50 shift plot (Arunlakshana and Schild, 1959) was plotted 
using the equation;  
EC50 = 10 ^ Log EC50;  
Antag = 1+ (B/ (10^ (-1*pA2))) ^ Schild Slope;  
LogEC = Log (EC50*Antag);  
Y = Bottom + (Top – Bottom)/ (1+10 ^ ((Log EC – X) * Hill Slope)), 
where  EC50 is the concentration of agonist that gives half maximal response, 
pA2 is the negative logarithm of the concentration of antagonist needed to 
shift the dose response curve by a factor of 2, Hill Slope describes the 
steepness of the family of curves, Schild Slope quantifies how well the shifts 
correspond to the prediction of competitive interaction and if the competitor is 
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competitive, the Schild Slope will equal 1.0, and Top and Bottom are plateaus 
in the units of the Y axis. 
 In Schild EC50 shift concentration–response curve plots, a competitive 
antagonist would shift the agonist concentration–response curve to the right 
with no change in the apparent maximum response obtained, whereas the non-
competitive antagonist reduces the maximum response.  
Each data point represents the average ± S.E.M. of three independent 
experiments. Computation was done using GraphPad Prism 6.03 (GraphPad 
software, Inc., La Jolla, CA, USA). 
Figure 2.3 Schematic representations of mRNA preparation, micro-injection and 
expression of nAChRs on Xenopus oocytes for two-electrode voltage clamping 
experiments.  
Radioligand binding assay with acetylcholine binding protein 
Determination of affinity of Oh9-1 towards acetylcholine binding protein 
(AChBP), a homolog of the ligand-binding (amino-terminal) domain of 
nicotinic receptors, isolated from marine and fresh water snails (Smit et al, 
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2001; Brejc et al, 2001; Brejc et al, 2002; Hansen et al, 2004 and Bourne et al, 
2005), using radio ligand binding assays was employed with an ultimate aim 
of co-crystallization.  
The interaction studies of Oh9-1 with acetylcholine binding protein 
(AChBP), described below were carried out in the collaborating laboratory of 
Professor Palmer Taylor, Skaggs School of Pharmacy and Pharmaceutical 
Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, 
California 92093, United States of America. 
An anti-mouse scintillation proximity assay (SPA; Amersham Biosciences, 
Piscataway, NJ, USA) was adapted for use in a soluble radioligand binding 
assay as described previously (Hibbs et al., 2004; Utsintong et al., 2009). A 
total of three soluble acetylcholine-binding proteins (AChBP) were used for 
the study: AChBP from the freshwater snail Lymnaea stagnalis (Ls), and 
AChBP from the marine snail Aplysia californica (Ac) together with its α7 
mutant AcY55W (Hansen et al., 2005; Talley et al., 2006). All the binding 
proteins were recombinantly expressed and purified in Professor Palmer 
Taylor’s lab (UCSD, San Diego, CA, USA). AChBP (final concentration ~500 
pM binding sites for Ls AChBP; ~1 nM binding sites for Ac AChBP and its 
mutant), polyvinyl toluene anti-mouse SPA scintillation beads (0.1 mg/ml), 
monoclonal anti-FLAGM2 antibody from mouse, and [
3
H] epibatidine (5 nM 
final concentration for Ls, 20 nM for Ac and its mutant) were combined in a 
phosphate buffer (0.1 M, pH 7.0) with fixed concentrations of Oh9-1 at 10 μM 
and 30 μM in a final volume of 48 μl. Nicotine (10 μM) and 
methyllycacolitine (1 μM) were used as positive controls. The resulting 
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mixtures were allowed to equilibrate at room temperature for a minimum of 2 
h and measured on a Beckman LS6500 liquid scintillation counter. The result 




Crystallization conditions for Oh9-1 were screened with Hampton research 
screens (Crystal Screen 1 HR2-110, Crystal Screen 2 HR2-112, PACT screen, 
Morpheus screen and Index HR2-144screen) using sitting-drop vapour-
diffusion method. The refolded lyophilized protein was dissolved in water and 
purified on Superdex-75 gel-filtration column (1 cm x 30 cm) equilibrated 
with 10 mM Tris-HCl, 100 mM NaCl buffer pH 7.4. Crystallization 
experiments were carried out with protein samples at 20 mg/ml and 40 mg/ml 
(tried only for Crystal Screen 2 HR2-112) concentrations of Oh9-1 and plates 
were set at room temperature (20-23ºC) and at 4ºC respectively. Equal volume 
of sample and reservoir buffer (0.2 μl) was mixed in a sitting drop and allowed 
to undergo vapour diffusion against 80 μl of the reservoir buffer.  After set up, 
the plates were observed weekly until one month followed by observation 
once a month. The crystals once got were subjected for optimization to 
generate diffraction quality crystals using hanging-drop vapour diffusion 
method. For X-ray diffraction data collection, the crystals were briefly soaked 
in reservoir solution supplemented with various cry protectants like 10% 
glycerol, 70% sucrose, 15% inositol, 2-propanol, PEG-400 and propylene 
glycol. Once data collected, the crystals were flash-freezed in liquid nitrogen 




2.3.1 Production of Oh9-1 
Cloning of synthetic gene to pET-22b vector 
Initial attempts using various vectors containing solubilization tags and 
expression systems that facilitate folding of the expressed protein were 
unsuccessful to express the protein in soluble form (Data not shown). 
Therefore, recombinant Oh9-1 devoid of expression tags was expressed in 
inclusion bodies. The codon optimization and the overall strategy for the 
design of constructs from synthetic gene are shown in Figures 2.4 and 2.5.   
 
CAT ATG CTT ATT TGT CAT CGT GTT CAT GGT CTT CAA ACT  
CAT ATG TTA ATC TGT CAT CGT GTC CAC GGC TTA CAA ACT 
H  MetL   I   C   HR   V   H   G   L   Q   T  
TGT GAA CCT GAT CAA AAA TTT TGT TTT CGT AAA ACT ACT  
TGC GAA CCA GAC CAG AAGTTTTGTTTTCGCAAAACCACG 
C   E   P   D   Q   K   F   C   F   R   K   T   T 
ATG TTT TTT CCT AAT CAT CCT GTT CTT CTT ATG GGT TGT  
ATG TTC TTC CCG AAT CAC CCG GTG CTG CTG ATG GGT TGC 
M   F   F   P   N   H   P   V   L   L   M   G   C  
ACT TCT TCT TGT CCT ACT GAA AAA TAT TCT GTT TGT TGT  
ACC AGC TCC TGC CCG ACG GAG AAA TAC AGC GTT TGT TGC 
T   S   S   C   P   T   E   K   Y   S   V   C   C  
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TCT ACT GAT AAA TGT AAT AAA TAA CCA TGG 
AGC ACC GAT AAA TGC AAC AAG TAA CCA TGG 
S T D K C NK   *P W 
Figure 2.4 Comparison of unoptimized and optimized sequences encoding 
Oh9-1. The sequence (5’-3’) of unoptimized DNA sequence of Oh9-1 (upper, bold) 
comparatively aligned with optimized synthetic gene for Oh9-1 (lower, unbold and 
shaded grey). Mentioned underneath the nucleotide sequence is the protein sequence of 
Oh9-1. Underlined Methionine residue depicts the first amino acid encoded by the open 
reading frame and asterisk denotes the stop codon. Amino acids restudies denoted in 
bold font are the basic residues of the expressed protein. 
 
 
Expected protein sequence of recombinant Oh9-1 expressed: 
Met L I C H R V H G L Q T C E P D Q K F C F R K T T M F F P N H P V L 
L M G C T S S C P T E K Y S V C C S T D K C N K Stop 
Expected Molecular mass of Oh9-1:6646.8 Da (with all the Cys reduced) 
                                                          6638.8 Da (with all the Cys oxidised) 
Theoretical pI of expressed Oh9-1: 8.48 
Figure 2.5 Schematic representation of expression construct of Oh9-1. The 
constructs used for transformation of pET-22b. The 5’ restriction site Nde I contributes 
to the start codon, thus starting the open reading frame. Therefore, recombinant Oh9-1 
was expressed containing methionine (encoded by start codon) as the extra amino acid 
and is devoid of any purification or solubilisation tags. 
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Recombinant expression of Oh9-1 
Optimization of the protein expression in E. coli was accomplished by 
changing different parameters such as bacterial strains (BL21(DE3), 
Rosettagami (DE3) and SHuffle cells), IPTG concentration (0.1 and 1 mM), 
temperature (18ºC and 37ºC) and incubation time (4-16 h) (results not shown). 
Oh9-1was expressed in E. coli SHuffle Lys-Y cells, which constitutively 
expresses a chromosomal copy of the disulphide bond isomerise DsbC. The 
protein was expressed in insoluble fraction in all the tried conditions. On the 
SDS-PAGE, insoluble fraction showed a protein band of apparent molecular 
mass of ~11 kDa, notwithstanding the expected mass of ~6.4 kDa (Figure 
2.6A). The same insoluble fraction sample run on gel was subjected RP-HPLC 
purification and a major peak corresponding to the calculated mass of 
recombinant Oh9-1 (confirmed by ESI-MS) was obtained. The apparently 
slow mobility on the gel of the untagged Oh9-1 could be attributed to several 
basic residues present in a protein (Figure 2.6 A). No significant difference in 
expression was observed on changing various parameters such as the 
concentration of IPTG used, except 0.1 mM concentration of IPTG when the 
expression was a little less in the insoluble fraction (Results not shown). As 
the yield of the protein was higher in the insoluble fraction the protein was 
directly refolded from this fraction. 
Inclusion body preparation 
The recombinant Oh9-1 expressed in E. coli was recovered from inclusion 
bodies using three inclusion body wash steps including reducing and 
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denaturing conditions (W1= Lysis buffer with 1% TritonX-100, W2= Lysis 
buffer with 1.5% β-mercaptaethanol and W3= Lysis buffer with 1 M Urea as 
shown in the Figure 2.6 A). The purified, solubilised and reduced inclusion 
body preparation was run on SDS-PAGE under reducing condition. After 
careful analysis of the gel, it was quite obvious that 1% Triton X-100 wash 
was sufficient to obtain pure inclusion bodies. As shown in Figure 2.6 A, the 
protein was almost homogenous and its yield from inclusion bodies was ~30 
mg of denatured protein from 1 L of culture. 
RP-HPLC purification of denatured and reduced Oh9-1 
Initially to confirm the purity and recovery of reduced protein, the solubilized 
and reduced inclusion bodies were subjected to purification by RP-HPLC 
using C18 column (Figure 2.6 B). A homogenous peak (indicated by arrow) 
corresponding to the molecular mass of reduced Oh9-1protein was detected. 
The mass determined by ESI-MS was 6647.36 ± 0.892 Da (Figure 2.6 C inset) 
that matched the calculated mass of reduced Oh9-1 (6646.9 Da). The HPLC 
profile and ESI-MS data confirm the homogeneity of the reduced protein. 
Refolding and RP-HPLC purification of refolded Oh9-1 
The reduced protein was refolded both from inclusion body preparation and 
purified freeze-dried protein as detailed in the Methods. The refolded protein 
was found to be eluting in a single peak, suggesting structural homogeneity 




Figure 2.6 Expression and purification of Oh9-1. A) SDS-PAGE analysis of 
Oh9-1 expression and preparation of inclusion bodies. M, Protein standards with 
molecular masses denoted on the left; UI, un-induced; In, induced at 37ºC for 4 h or 
16ºC for 16 h; Su, soluble fraction; Pe, pelleted insoluble fraction; W1-3, three stages of 
washing; IBs, prepared IBs. (B) Purification of denatured and reduced Oh9-1 on Jupiter 
C18 (5 μ, 300 Å, 10 mm×250 mm) column equilibrated with solvent A (0.1% TFA). The 
protein was eluted with a linear gradient of 32–42% of solvent B (80% ACN in 0.1% 
TFA) over 100 min at a flow rate of 2 ml/min. The dotted line indicates the gradient of 
buffer B. Arrow indicates the peak containing reduced Oh9-1. (C) ESI-MS spectrum of 
purified reduced Oh9-1. Inset, reconstructed mass spectrum of Oh9-1 showing a single 
homogenous protein with a mass of 6647.36 ± 0.89 Da. (D) Purification of refolded Oh9-
1 from purified, reduced Oh9-1. The refolded proteins were eluted with a linear gradient 
of 22–40% of solvent B over 60 min and 100 min at a flow rate of 1 ml/min and 2 
ml/min on Jupiter C18 (5 μ, 300 Å, 4.6 mm×250 mm) column. Arrow indicates the major 
conformer of refolded Oh9-1. (E) ESI-MS spectrum of refolded Oh9-1. Inset, 
reconstructed mass spectrum of refolded Oh9-1 showing a single homogenous protein 
with a mass of 6639.67 ± 0.53. (F) Far-UV circular dichroism spectra of Oh9-1 and 
ETxb. The proteins were dissolved in MilliQ water (20 µM) separately, and the CD 
spectra were recorded using a 0.1 cm path-length cuvette.  

















The refolded protein elutes earlier than elution buffer-B percentage of reduced 
protein indicating that the refolding has taken place, consequentially reducing 
overall surface hydrophobicity of the protein. The protein was found to be a 
correctly refolded protein of MW 6639.67 ± 0.5 Da as assessed by ESI-MS 
(Figure 2.6 E inset). The secondary structure of refolded protein was evaluated 
by CD-spectrometry. As shown in Figure 2.6 [F] Oh9-1 presents characteristic 
minima at 210 nm and maxima at 190 nm of strong beta-sheeted compatible 
with a 3FTx fold. Furthermore, the functional activity of this refolded Oh9-1 
was checked by ex-vivo organ-bath experiments. 
 
2.3.2 Functional characterisation of Oh9-1 
Ex vivo organ bath experiment using isolated CBCM  
For the pharmacological characterization of recombinantly expressed and 
refolded Oh9-1 on neuromuscular transmission, CBCM preparations were 
used. We evaluated the effects of recombinant Oh9-1 (rec-Oh9-1) on 
neurotransmission in CBCM preparations. Rec-Oh9-1 (100 μM) produced a 
neuromuscular blockade of EFS-evoked twitch responses in chick biventer 
cervicis muscle (CBCM) preparations (Figure 2.7A). It inhibited the 
contractile response to the exogenous agonists, acetylcholine (ACh) and 
carbachol (CCh), whereas response to exogenous KCl and twitches evoked by 




Figure 2.7 Pharmacology profile of Oh9-1 on Chick biventer cervicis 
muscle (CBCM). (A) Representative muscle contraction traces showing the effect of 
Oh9-1 (100 µM), and (B) reversibility of the neuromuscular block in CBCM 
preparations. Contractions were produced by exogenously added ACh (300 μM), CCh 
(10 μM), and KCl (30 mM). The horizontal black bar indicates the electrical field 
stimulation (EFS). The points of washes with Krebs solution in reversibility studies are 
indicated as ‘Wash’. The block is calculated as a percentage of the control twitch 
responses to supramaximal nerve stimulation. (C) Traces showing the effect of Oh9-1 
(10 µM and 30 µM) on CCh-induced contraction of CBCM. (D) Concentration-response 
curves of Oh9-1 towards EFS and CCh in CBCM.  Each data point is the mean ± S.E.M 
of at least three experiments.  
Neuromuscular blockade of EFS- and CCh-evoked responses in CBCM 
was reversible (Figure 2.7B, C). Rec-Oh9-1 exhibited concentration-
dependent blockade, with IC50 values of 31.03 μM (95% Cl 25.5–37.8) and 7.2 
μM (95% Cl 6.2–8.5) on EFS- and CCh-evoked responses, respectively 
(Figure 2.7D). Variation in the affinities and reversibility of native and rec-
Oh9-1 could be attributed to (i) contamination of native Oh9-1 with 
undetectable amounts (using mass spectrometry) of high-affinity 3FTxs from 
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venom, and/or (ii) the presence of additional Met at the N-terminal. Despite 
the lack of all the functionally important residues of α-neurotoxins, rec-Oh9-1 
shows reversible, postsynaptic blockade.  
 
Electrophysiological studies of Oh9-1 
a) Subtype selectivity and concentration-response studies of Oh9-1 
In order to obtain a subtype selectivity profile, Oh9-1 at 
††
100 μM 
concentration was screened for its effect on currents evoked by EC50 
concentrations of ACh for each nAChR subtype expressed on Xenopus oocyte. 
Ten different nAChR subtypes from human and rat namely rat muscle type 
[both adult (α1β1εδ) and fetal (α1β1γδ)], human neuronal α7, α9α10, α4β2, 
α4β4, α3β2, α3β4 and rat neuronal α3β2and α4β2 subtypes, were screened 
(Figure 4.8A). Oh9-1 was more selective towards [both adult (α1β1εδ) and 
fetal (α1β1γδ)] muscle type and rat neuronal α3β2 nAChR (Figure 2.8 B) 
compared to the other subtypes tested. At 
‡‡
100 μM concentration, Oh9-1 
showed more than 95% to 100% inhibition on α1β1εδ and α1β1γδ subtypes. 
On rat α3β2 Oh9-1 showed    70% to 75% inhibition, whereas it inhibited 
human α3β2 around 30% to 40%, indicating specificity towards rat α3β2 than 
human α3β2. Oh9-1 showed less or no inhibition on other receptor subtypes 
that were tested.  
                                                 
††
  
Oh9-1 showed more than 90% inhibition at 30 μM concentration on rat muscle type αβγδ 
receptor subtype. Therefore, Oh9-1 was not tested at higher concentration.  
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 Further, the binding parameters of Oh9-1 was determined on [muscle type 
(α1β1εδ and α1β1γδ), and rat neuronal α3β2] receptor. These two subtypes are 
the main targets of Oh91 in term of affinity. Oh9-1(0.3-100μM; n = 3) could 
inhibit the currents evoked by ACh in a dose-dependent manner for the above 
mentioned subtypes (Figure 2.8 C). At 10 μM and 100 μM of Oh9-1, the 
response to EC50 concentrations of ACh was completely inhibited on muscle 
type (α1β1εδ and α1β1γδ) and rat α3β2 subtypes. The IC50 of Oh9-1 for 
α1β1εδ, α1β1γδ and rat α3β2 nAChR subtypes was further determined to be 
3.1 ± 1.1 µM, 5.6 ± 1.1 µM and 50.2 ± 1.1 µM, respectively, indicating that 
Oh9-1 antagonizes these nAChR subtypes at micro-molar concentrations 
(Figure 2.8 C). Hill’s coefficient of Oh9-1 binding to α1β1εδ, α1β1γδ and rat 
α3β2 were determined to be -0.9, -1.65, -1.7, respectively, suggesting that 
Oh9-1binding does not mediate any cooperativity in ligand-receptor 
interaction (Langley, 1905; Prinz, 2010; Prinz and Maelicke, 1983) (Edelstein 
and Le Novère, 2013). This result indicated that each molecule of Oh9-1 
bound to the receptor does not affect the affinity for the second molecule to 
bind. It should be noted that there are two non-identical ligand-binding sites on 
both α1β1εδ and α1β1γδ nAChR i.e., at interfaces; α/δ, α/γ and α/δ, α/ε 
respectively, whereas in α3β2 there are two identical ligand-binding sites i.e., 
at interfaces; α3/β2 and Oh9-1 binds to different ligand –binding sites within a 
receptor subtype, with similar affinities. 
Oh9-1 lacks all the previously described critically important residues 
for 3FTxs to interact with nAChRs. Despite this replacement, Oh9-1 still 




Figure 2.8 Inhibition of nAChR subtypes expressed in Xenopus oocytes 
by Oh9-1. (A) Representative superimposed traces of inhibition of ACh-evoked 
currents at EC50 concentrations recorded in the absence (—) or presence (---) of Oh9-1. 
Determined ACh EC50s of hα7, rα3β2, rα1β1δγ (fetal) and rα1β1δε (adult) receptors are 
100, 10, 1 and 1 μM, respectively. (B) Bar graph illustrating the nAChR subtype 
selectivity of Oh9-1. (C) Concentration–response curves of Oh9-1 on selective nAChR 
subtypes gave IC50s of 3.1 µM (95% Cl 2.6–3.6), 5.6 µM (95% Cl 4.1–7.5) and 50.2 µM 
(95% Cl 44.9–56.2) for rα1β1δε (adult), rα1β1δγ (fetal) and rα3β2 receptors, 
respectively. Each data point is the mean ± S.E.M of at least three experiments.   
b) Competitive binding studies of Oh9-1 
We have further analysed the mode of interaction of Oh9-1 on muscle 
receptor in order to determine if the replacement of the canonical residues 
can lead to a different binding site (non-competitive allosteric antagonism) 
or mode of interaction (competitive orthosteric antagonism through 
different interactions).  
A 
 








Figure 2.9 Oh9-1 is a competitive antagonist of ACh on rα1β1δε. (A) 
Representative superimposed traces of ACh-evoked responses in the absence or presence 
of Oh9-1. (B) Concentration–response curves obtained from the traces of ACh-evoked 
responses in the absence (Δ) or presence of Oh9-1at 3 µM (□) and 10 µM (○). Each data 
point is the mean ± S.E.M of at least three experiments.  
We have used schild EC50 shift concentration-response curve plot 
(described in methods section) to determine the mode of antagonism 
(competitive or non-competitive) of Oh9-1. In schild EC50 shift 
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concentration–response curve plot (Figure 2.9 B), a competitive antagonist 
would shift the agonist dose response curve to the right with no change in 
the apparent maximum response obtained, whereas the non-competitive 
antagonist depresses the maximum response. This result indicates that 
Oh9-1 is a competitive antagonist of ACh with a pA2 value of -0.83 (95% 
confidence interval: -1.042 to -0.5857), as Oh9-1 shifts the agonist dose 
response curve to the right with no change in the apparent maximum 
response obtained, at both 3 μM and 10 μM concentrations . 
c) Cys-loop receptor selectivity of Oh9-1 
 We also tested Oh9-1 for its cross-reactivity with Cys-loop human 
receptors other than nAChRs; hα1β2γ2 and hρ1 subtypes among GABAA and 
hGlyRα1 subtype of glycine receptors. Rec-Oh9-1 did not inhibit these 
receptor types even at 30 μM concentration (Figure 2.11). Interestingly, 
concentration-independent potentiation was observed on GlyRα1 receptors 
from 100 µM to < 1 pM rec-Oh9-1 (data not shown). Hence, we conclude that 





Figure 2.10 Selectivity profile of Oh9-1 on other Cys-loop receptors. (A) 
Representative superimposed traces of inhibition of agonist -evoked currents recorded in 
the absence (—) or presence (---) of 30 µM Oh9-1. (B) Bar graph illustrating effects of 











Radioligand binding assay with acetylcholine binding protein 
The soluble acetylcholine-binding protein (AChBP) is a structural 
homologue of the extracellular ligand binding domain of muscle-type and 
neuronal nAChRs (Smit et al, 2001; Brejc et al, 2001; Hansen et al, 2004) and 
a good nAChR substitute. There are successful examples of co-crystallization 
structures of α-cobratoxin with AChBP from the freshwater snails, Lymnaea 
stagnalis (Ls) (Bourne et al., 2005), and additional success seen in AChBP 
from the marine species, Aplysia californica (Ac) and its mutant (AcY55W) 
with α-neurotoxins and conotoxins (Kasheverov et al., 2009). Therefore, 10 
μM and 30 μM of Oh9-1was screened for its ability to compete or interfere 
with the binding of [
3
H] epibatidine to these AChBPs (Ls, Ac and the Ac 
mutants, AcY55W), as measured by a scintillation proximity assay (Figure 
2.10).   As shown in the figure Oh9-1 failed to show significant interference 
for the binding of [
3
H] epibatidine to the binding proteins, either at the higher 
concentration. These results suggested that either Oh9-1 did not interact with 
the binding protein. Significant interference for the binding of [
3
H] epibatidine 
to the binding proteins was observed with 10 μM nicotine and 1 μM MLA 




Figure 2.11 Interaction of Oh9-1 with acetylcholine binding protein 
(AChBP) and its mutants. Comparison of competitive radioligand binding assays of 
Oh9-1 and acetylcholine binding proteins (Ls: Lymnaea stagnalis; Ac: Aplysia 
californica and Ac y55W mutants). The concentrations of Oh9-1 used were 10 μM and 
30 μM. Nicotine (10 μM) and methyllycaconitine (1 μM) were used as positive controls. 
The radioligand used was [
3
H] epibatidine. Results are expressed as fraction of 
epibatidine binding. 
 
2.3.3 Structural characterisation of Oh9-1 
Monomeric nature of Oh9-1 
As described earlier 3FTxs could are functional as monomers and dimers. 
Therefore, it was interesting to investigate the oligomeric nature of Oh9-1. 
With the purified protein gel filtration chromatography was performed to gain 
an idea about the relative molecular weight (Mr) of Oh9-1 and thereby the 
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oligomeric state of the protein. We carried out analytical gel filtration 
experiments using a Superdex G-75 column. Protein at concentrations 3 µM 
(data not shown), 10 µM (data not shown) and 30 μM (data shown) was 
loaded onto the column. At these concentrations, the presence of a single peak 
corresponding to a relative molecular weight (Mr) of 6.45 kDa was observed, 
indicating that Oh9-1 is a monomer. 
 
Figure 2.12 Refolded Oh9-1 is a monomer at physiological pH. Gel filtration 
profile of Oh9-1. Refolded Oh9-1 (30 µM) was loaded onto a Superdex 75 column (1 x 
30 cm) and equilibrated with 50 mM ammonium bicarbonate buffer (pH = 7.4) and 
eluted with the same buffer at 1 ml/min flow rate. Inset, The standard curve of elution 
volumes of proteins plotted against their masses; I = Bovine serum albumin, II = 
Carbonic anhydrase, III = Cytochrome c, IV = Aprotinin. The mass of refolded Oh9-1 
was determined by its elution volume (dotted lines) 
 
Determination of Secondary structure of Oh9-1 by CD spectroscopy 
The CD spectrum of refolded Oh9-1(peak marked with arrow; Figure 2.6 D, 
also tested for activity) shows maximum at 210 nm and a minimum at 190 nm 
(Figure. 2.6 F). Thus, Oh9-1 was found to be composed of β-sheeted structure 
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similar to other 3FTxs (Compared with classical Type-I short chain 3FTx, 
Erabutoxin B).  
Determination of three-dimensional structure of Oh9-1 
Ultra-violet (UV) Circular Dichroism (CD) spectroscopy can only 
determine secondary structure of proteins. However, to determine the three-
dimensional (3D) structure of the protein, the two techniques that have been 
widely used in structural biology are: single-crystal X-ray diffraction and 
nuclear magnetic resonance (NMR) spectroscopy. 
Among all the crystallization screens used, stacked crystals were produced 
in 20 mg/ml at room temperature (20-23ºC) and 40 mg/ml at 4ºC only in one 
conditions [F9] of crystal screen HR2-112 (condition F9: 0.1 M MES 
monohydrate, pH=6.5, 0.1 M sodium phosphate monobasic monohydrate, 0.1 
M potassium phosphate monobasic and 2M sodium chloride). The crystal 
obtained in this condition was optimized for better diffraction quality by 
preparing grid screens of varying concentration of NaCl (1 M to 2 M) and pH 
(6.3 to 6.8) both at 20 mg/ml at room temperature (20-23 ºC) and 40 mg/ml at 
4ºC. However, the crystals obtained in these optimizations were not of 
necessary diffracting quality. Therefore, further optimisation for obtaining 
good quality crystals is still in progress. 
Good quality individual crystals were produced in 20 mg/ml at room 
temperature (20-23ºC) in one condition of Index HR2-144screen (0.1 M Tris 
pH 8.5, 25% w/v Polyethylene glycol 3,350). Further optimisation of this 
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condition to obtain good diffracting quality crystal is in process. 
 
Figure 2.13 Crystals of Oh9-1 obtained in Index HR2-144 screen condition; 0.1 M Tris 
pH 8.5, 25% w/v Polyethylene glycol 3,350 
 
2.4 Discussion 
The members of 3FTx toxin family share similar protein-folding patterns.  
They have three β-stranded loops extending from a central core that is 
stabilized by four conserved disulphide bonds (Kini and Doley, 2010). Despite 
the overall similarity in structure, the polypeptides differ markedly in their 
biological targets. Neurotoxins interact with nAChRs [reviewed in  (Kini and 
Doley, 2010; Tsetlin, 2015)]; cardiotoxins or cytotoxins interact with 
phospholipids and cell membranes (Gasanov et al., 2014); and aminergic or 
muscarinic toxins interact with biogenic amine receptors and muscarinic 
acetylcholine receptors (Blanchet et al., 2014; Servent and Fruchart-Gaillard, 
2009); fasciculins inhibit acetylcholinesterases (Anderson et al., 1985); 
calciseptines interact with Ca
2+
 channels (de Weille et al., 1991); dendroaspins 
interact with integrins (McDowell et al., 1992); hemextins inhibit factor VIIa 
(Banerjee et al., 2005a); mambalgins block acid-sensing ion channels (Diochot 
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et al., 2012); and micrurotoxins interact with GABAA receptors (Rosso et al., 
2015).  Thus, small alterations in 3FTx amino acid sequence do not change the 
overall protein scaffold, but elicit distinctly different pharmacological 
functions (Kini and Doley, 2010). Understanding these subtle structure–
function relationships is challenging, but will provide important insights into 
the specific determinants of biological activity.    
Oh9-1 is similar (77-98% identity) to eight 3FTxs from O. hannah venom. 
It exhibits 51% identity  to CM-1b from Hemachatus haemachatus venom 
(Joubert and Taljaard, 1980) and 46% identity to mambalgin-1 from 
Dendroaspis polylepis venom (Diochot et al., 2012) (Figure 2.0A). Oh9-1 
shares less than 33% sequence identity with α-neurotoxins (Figure 2.0B); it 
has much shorter loops-I and -III (5- and 3-residues shorter, respectively) and 
an extra residue in loop-II (Table 2.1). Further, the functional residues of α-
neurotoxins (Figure 2.0B, shaded grey) are not conserved in Oh9-1. These 
structural differences provided the impetus for our detailed characterization of 
Oh9-1.  
In this chapter, we have described structural and functional characterisation 
of novel three-finger toxin, Oh9-1. Oh9-1 was recombinantly expressed, 
refolded and purified to homogeneity. In addition, the monomeric nature of 
Oh9-1 was confirmed by analytic gel filtration profile, where Oh9-1 elutes at 
the retention volume as aprotinin (6.5 kDa). Pharmacological characterisation 
of recombinant Oh9-1 revealed that despite the lack of all the functionally 
important residues of α-neurotoxins, rec-Oh9-1 shows reversible, postsynaptic 
micromolar blockade. This proved that Oh9-1, despite the lack of functional 
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site described in α-neurotoxins has exerted its biological function by blocking 
the neuromuscular junction, but at micro-molar concentrations in comparison 
to nano-molar activity found for the α-neurotoxins. While, native Oh9-1, 
isolated from king cobra venom was reported to irreversibly inhibit carbachol-
induced muscle contraction in CBCM with an IC50 of 88.0 nM (Chang et al., 
2002). Variation in the affinities and reversibility of native and rec-Oh9-1 
could be attributed to (i) contamination of native Oh9-1 with undetectable 
amounts (using mass spectrometry) of high-affinity 3FTxs from venom, and/or 
(ii) the presence of additional Met at the N-terminal 
 





Interpreting these results and observations, it is evident that Oh9-1in 
comparison to α-neurotoxins has a completely different and novel functional 
site for interacting with nAChRs. Therefore, whether Oh9-1 interacts with the 
same site as α-neurotoxins on nAChRs became the immediate question of 
interest. 
Interestingly, Oh9-1, with its different nAChR interacting functional 
residues, showed competitive antagonism towards ACh binding pocket of 
nAChRs. This suggests that Oh9-1 binds at ACh binding site of nAChR as α-
neurotoxins, but with different molecular recognition determinants, which has 
not been described so far in α-neurotoxins.  
Additionally, we investigated the selectivity for 10 different nAChR 
subtypes, namely rat muscle-type [adult (rα1β1εδ) and fetal (rα1β1γδ)], human 
neuronal hα7, hα9α10, hα4β2, hα4β4, hα3β2 and hα3β4, and rat neuronal 
rα3β2 and rα4β2 subtypes (Figure 4). Oh9-1 was selective for muscle-type 
rα1β1εδ/rα1β1γδ (adult/fetal) and neuronal rα3β2 subtypes. It weakly blocks 
hα3β2 and hα3β4, but none of the other nAChRs, even at 100 µM (Figure 4B). 
The IC50 values of Oh9-1 for these subtypes were 3.1 µM (95% Cl 2.6 – 3.6), 
5.6 µM (95% Cl 4.1 – 7.5) and 50.2 µM (95% Cl 44.9 – 56.2), respectively. 
The Hill coefficient of Oh9-1 binding to rα1β1εδ, rα1β1γδ and rα3β2 were -
0.9, -1.65, -1.7, respectively, suggesting non-cooperative ligand-receptor 
interaction (Prinz, 2010). Rec-Oh9-1 shows concentration-dependent effects in 
the micromolar range, whereas α-neurotoxins show nanomolar level activity. 
Similar to short-chain α-neurotoxins, Oh9-1 showed selectivity towards 
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muscle-type rα1β1εδ/rα1β1γδ (adult/fetal) receptors. Interestingly, unlike 
short-chain α-neurotoxins, Oh9-1 also blocked the neuronal rα3β2 subtype.  
Furthermore, to determine the cross-reactivity of Oh9-1 with other Cys-
loop receptors than nAChRs, we screened Oh9-1 at 30 μM concentration on 
hα1β2γ2 and hρ1 subtypes among GABAA and hGlyRα1 subtype of glycine 
receptors. Although Oh9-1 did not inhibit these receptor types, concentration-
independent potentiation was observed on GlyRα1 receptors from 100 µM to 
< 1 pM rec-Oh9-1 (data not shown). Hence, we concluded that of the Cys-loop 
receptors we tested, Oh9-1 selectively blocks nAChRs. 
  Driven by the finding, that Oh9-1 interacts with same site as α-neurotoxins 
on nAChRs but with entirely different functional site, it was interesting for us 
to delineate the molecular recognition site of this Ω-neurotoxin. In this regard 
approches of complex formation with AChBP with an ultimate aim of co-
crystallization was tried. We observed the interaction between Oh9-1and 
AChBP using competitive radioligand binding assay. As shown in the results 
Oh9-1 did not show any competition with epibatidine to interact with the 
AChBP or its mutant. This could be because of the specificity of Oh9-1 
towards vertebrate nicotinic acetylcholine receptors and not to the invertebrate 
analog.  
Subsequently, with the aim of gaining insights on the structure of this Ω-
neurotoxin, attempts were also made to obtain diffracting quality crystals of 
Oh9-1, in order to determine the three-dimensional structure of Oh9-1. We 
have seen positive hit for one of the conditions in the initial crystal screen 
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conditions tried and further optimisation of this condition for obtaining good 
quality crystals is still in progress. It would be really interesting to determine 
the 3D structure of Oh9-1. If protein crystals are not obtained then nuclear 
magnetic resonance (NMR) can be used to determine its structure.  
2.5 Conclusions 
In conclusion, we describe the structural and functional characterisation of 
Oh9-1, a novel Ω-neurotoxin. The novel and interesting findings of this 
characterisation further led us to delineate the functional site as well as 
elucidate the structure-function relationship of Oh9-1, which is described in 
























Delineating the molecular recognition site of a protein is quite a challenging 
task. This can be acheieved by many different approches. One is the 
identification of structural epitopes from the threedimensional structure of the 
protein, preferably by co-crystallizing the ligand-receptor complex 
(Cunningham and Wells, 1993). For example the co-crystallization of along-
chain α-neurotoxin, α-cobratoxin with acetylcholine binding protein (AChBP), 
a homolog of the ligand-binding (amino-terminal) domain of nicotinic 
receptors, isolated from marine and fresh water snails (Smit et al, 2001; Brejc 
et al, 2001; Brejc et al, 2002;Hansen et al, 2004 and Bourne et al, 2005). 
However, with the proteins which cannot form a complex with the structural 
homolog, for example most of short-chain α-neurotoxins do not bind to 
AChBP, the functional determinants of a protein can also be analyzed 
usingsite-directed mutagenesis, chemical modification and design of synthetic 
peptides derived from potential interaction sites. On the other hand molecular 
modeling based on known structural templates (Menez, 1998; Servent and 
Menez, 2001) can also be employed to get a preliminary idea. These methods, 
in combination with available literature on the tertiary structure of 
neurotoxins, has led to more accurate delineation of the interaction sites by 
which different classes of neurotoxins recognize various subtypes of nicotinic 
acetylcholine receptors (Pillet et al, 1993; Trémeauet al, 1995; Servent et al, 
1997; Grant et al, 1998; Antil et al, 1999; Antil-Delbeke et al,2000; Boulain 
and Menez, 1993; Zeng et al, 2001; Moise et al, 2002; Bourne et al, 2005 
;Dellisanti et al, 2007). 
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As discussed earlier, we have recombinantly expressed and characterized 
Oh9-1, a member of the novel class of three-finger neurotoxin family, Ω-
neurotoxins, with unique structural and functional profile. In Chapter two, the 
detailed strutural and functional characterisation of Oh9-1 revealed that  Oh9-
1, the monomeric Ω-neurotoxin, is a compettive antagonist of nAChR and 
interacts with ACh binding pocket but with entirely different functional site 
than α-neurotoxins. With the aim of delineating the molecular recognition site 
of Oh9-1 for nAChRs, approches of complex formation with AChBP with an 
ultimate aim of co-crystallization and crystallization of Oh9-1 alone, were 
tried. However, both the approches did not yeild any successful results 
(described in Chapter 2). Therefore, delineation of the functional determinants 
of a protein using alanine scanning site-directed mutagenesis approach was 
employed. In this regard, we came up with 12 alanine scanning mutants 
encompassing the tips of all the three loops of Oh9-1 (Figure 3.0).  
In this chapter, we describe the production of 12 alanine mutants of Oh9-1 
and the results of screening these mutants on nAChR subtypes, towards which 
wildtype Oh9-1 was highly selective. With these results, we describe the 











Figure 3.0 Oh9-1 amino acid sequence. Highlighted amino acid residues are individually mutated to alanine. Mutations are done at tip regions of all the 
three loops. Toxin name, species, and (ACCN) accession number is shown. Disulphide bridges and loop regions are also shown. A t the end of the sequence, the 
number of amino acid residues is stated. Residues highlighted in pink are mutated to alanine and expressed as 12 alanine single mutants of Oh9 -1. 
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3.2 Materials and Methods 
3.2.1 Materials 
The 12 alanine scanning mutant genes of Oh9-1 cloned into pET-22b 
expression vector were ordered from GenScript USA Inc, 860 Centennial Ave, 
Piscataway, NJ 08854, USA. All other materials and reagents used are as 
listed in chapter two, section 2.2.1 
3.2.2 Animals 
As described in chapter two, section 2.2.2. 
3.2.3 Methods 
Transformation of clone and expression host strains 
All the mutant clones were transformed into E. coli SHuffle T7 Lys-Y 
expression host strains and glycerol stocks were prepared as described in 
chapter two, section 2.2.3. 
Recombinant expression, refolding from IBs, purification and mass 
determination 
As described in chapter two, section 2.2.2 under respective headings. 
Electrophysiological studies of Oh9-1alanine mutants 
Electrophysiological studies of Oh9-1alanine mutants were conducted as 




3.3.1 Production of Oh9-1 alanine mutants 
By using a strategy that was previously successfully applied to the 
production of wild-type Oh9-1, 12 alanine mutants of Oh9-1 were produced in 
cytoplasm of E.coli as inclusion bodies (IBs). Mutants were prepared in 
satisfactory yields, not much different from that observed for the wild-type 
toxin.  
Some mutants such as H7A, T23A and F26A had lesser yields of about ~10-15 
mg/L culture. These mutants were further refolded from partially purified IBs 
and purified by RP-HPLC (Figure A.3 in Appendix). They displayed the 
expected refolded mass, as determined by electrospray mass analysis. 
Molecular mass of the refolded mutants were assessed by ESI-MS (Figure A.3 
in Appendix). The secondary structure of refolded mutants was evaluated by 
CD-spectrometry. As shown in Figure 3.1 [B] Oh9-1 mutants show 
characteristics of beta sheet secondary structures, compatible with a 3FTx fold 





Figure 3.1 Production of alanine mutants of Oh9-1. A) Expression of 12 
alanine mutants of Oh9-1 in E. coli was analysed by Tricine SDS/PAGE. Samples were 
resolved by Tricine SDS/PAGE (15% gel) and stained with SimplyBlue™ Safe Stain. 
Lane M, Precision Plus Protein Dual Xtra Standards with molecular masses to the left-
hand side; lane UI, un-induced; lane In, induced at 37ºC for 4 hours and are labelled with 
respective alanine mutants. (B) Far-UV CD spectrum of alanine mutants, wild-type Oh9-
1 and Erabutoxin-B. The proteins were dissolved in MilliQ water (20 µM) separately, 









Table 3.1 Reduced and refolded mass of alanine mutants of Oh9-1 
 
 
3.3.2 Alanine mutagenesis reveals key residues of Oh9-1-
nAChR functional site 
Electrophysiology experiments of Oh9-1 mutants 
  Because wild-type Oh9-1 was more selective towards α1β1εδ and rat α3β2 
nAChR subtypes with IC50’s of 3.1 ± 1.1 µM and 50.2 ± 1.1 µM, respectively. 
In order to understand the structure-activity relationship of Oh9-1, we tested 
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Figure 3.2 Alanine mutagenesis reveals key residues of Oh9-1-nAChR 
functional binding site. Bar graph illustrating the effects of wild-type Oh9-1 and its 
alanine mutants on rat muscle-type rα1β1δε (A) and neuronal rα3β2 (B) nAChRs at 10 
µM and 100 µM, respectively. Each data point is the mean ± S.E.M of three experiments. 
Statistical analysis is with one-way ANOVA; ***p < 0.001, **p < 0.01, *p < 0.05. # 
indicates statistically significant gain in activity. Filled bar is the control response for 
wild-type Oh9-1. Insets are the representative superimposed traces of inhibition of ACh-
evoked currents recorded in the absence or presence of alanine mutants of Oh9 -1 (M25A 








a) Screening Oh9-1 alanine mutants on rat muscle-type α1β1εδ nAChR 
We screened Oh9-1 mutants at a concentration of 10 μM (more than the 
IC50 concentration of Oh9-1) on α1β1εδ nAChR subtype and compared the 
activity with that of 10 μM wild-type Oh9-1. Mutation to alanine at positions 
T23, T24, M25, F26, F27 of loop-II and K45 of loop-III, showed significant 
loss in the activity of Oh9-1 (statistically analysed by One-way ANOVA test 
;***p < 0.001). Mutation of H30 to alanine showed an intermediate loss (**p 
< 0.01) and mutation at positions H7 and K22 showed less significant loss in 
the activity of Oh9-1 (* < 0.05), whereas the alanine mutations of N29 and 
V32 showed neither loss nor gain in the activity of Oh9-1. In contrast, we 
observed gain in the activity of Oh9-1 with alanine mutation at position Y46 
(* < 0.05) (Figure 3.2 A). These results indicate the significant functional role 
of residues at the tip of loop-II and loop-III in Oh9-1 to antagonise α1β1εδ 
nAChR. 
b) Screening Oh9-1 alanine mutants on rat neuronal α3β2 nAChR 
We screened Oh9-1 mutants at a concentration of 100 μM (more than the 
IC50 concentration of Oh9-1) on rat α3β2 nAChR subtype and compared the 
activity with that of 100 μM wild-type Oh9-1. Mutation to alanine at positions 
M25, F27 and H30 of loop-II showed significant loss in the activity of Oh9-1 
(statistically analysed by One-way ANOVA test; ***p < 0.001). Mutation of 
H7 and K22 to alanine showed an intermediate loss (**p < 0.01) and mutation 
at positions K45 showed less significant loss in the activity of Oh9-1 (* < 
0.05), whereas the alanine mutations of T23, F26, N29 and V32 showed 
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neither significant loss nor gain in the activity of Oh9-1. In contrast, we have 
observed significant gain in the activity of Oh9-1 with alanine mutation at 
position T24 (* < 0.05) and Y46 (*** < 0.001) (Figure 3.2 B). These results 
indicate the significant functional role of residues at the tip of loop-II in Oh9-1 
to antagonise α3β2 nAChR subtype. 
Thus, alanine scan of Oh9-1 has revealed distinct set of functionally 
significant residues to interact with α1β1εδ and rat α3β2 nAChR subtypes. 
 
3.4 Discussion 
To delineate the functional site of Oh9-1 and determine the feasibility of 
studying the crystal structure of the toxin–receptor complex, we evaluated the 
interaction between rec-Oh9-1 and AChBPs. Unfortunately, Oh9-1 did not 
compete with the interaction of radiolabeled epibatidine with AChBPs (Figure 
2.11). Therefore, we used alanine scanning site-directed mutagenesis approach 
to determine the functional site of Oh9-1.  
Alanine scanning approach to delineate the functional site by of a protein is 
long known and a reliable method (other than the structural analysis), used for 
decades with good results. To understand the structure-function relationships 
of 3FNTxs, extensive mutational studies have been carried out in short-chain 
and long-chain α-neurotoxins and functional determinants crucial to 
antagonise nAChRs have been described, in the past two decades (Antil et al., 
1999; Tremeau et al., 1995). These findings were also supported by structural 
analysis of α-neurotoxins (Bourne et al., 2005) (Huang et al., 2013).  In this 
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chapter, we report the delineation of functional determinants of Oh9-1, the 
member of a novel class of three-finger neurotoxins (Ω-neurotoxins) through 
alanine scanning mutational analysis. 
Alanine mutagenesis reveals key residues of Oh9-1-nAChR functional 
binding site - 
We individually mutated to alanine the residues at the tip-regions of three 
loops, except the proline residues; P28 and P31 (Figure 3.0). All 12 mutants 
were recombinantly expressed in E. coli (Figure 3.1A). All mutants were 
refolded from their respective IBs and purified by RP-HPLC. The refolded 
mutants showed masses corresponding to the calculated values (Table 3.1). 
Circular dichroism (CD) spectra of all mutants were similar to wild-type Oh9-
1 (Figure 3.1B), indicating that mutations did not affect overall structure of the 
toxin. We then investigated the effects of these single mutations on ACh-
evoked currents at nAChR subtypes (rα1β1δε and rα3β2) (Figure 3.2). Oh9-1 
mutants were screened at the respective nAChR subtype at a higher 
concentration than the IC50 of rec-Oh9-1 (10 μM for rα1β1δε and 100 μM for 
rα3β2 nAChR) (Figure 3.2). Similar to α-neurotoxins, loop-II residues appear 
crucial for binding to both nAChRs. However, residues encompassing loops-I, 
-II and -III distinguish the receptor subtypes. One of the β-strands in loop-II, 
T23-T24-M25-F26-F27, plays an important role in interaction with the 
rα1β1δε receptor and mutation of any of these residues led to almost complete 
loss of activity (Figure 3.2A). Alanine mutations of H7 (loop-I), K22 and H30 
(loop-II), and K45 (loop-III) also led to substantial loss of activity. 
Interestingly, although at the tip of loop-II, mutation of N29 and V32 had no 
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impact on activity. Mutation of Y46 significantly enhanced activity (Figure 
6A). In the case of Oh9-1-rα3β2 interactions, distinct residues are involved. In 
loop-II, mutations of M25 and F27 that both face the same side of the b-strand 
led to significant loss of activity (Figure 3.2B). Mutations at T23 and F26 
caused significant loss of interaction with rα1β1δε but had no effect on the 
interaction with rα3β2. Similarly, mutations at H7, K22, and H30 in loop-II 
and K45 in loop-III of Oh9-1 differ significantly in their impact on inhibition 
of Oh9-1 at these two subtypes. As with the rα1β1δε receptor, mutation of N29 
and V32 residues did not affect activity of Oh9-1 at rα3β2. Y46A (loop-III) 
also increased activity at rα3β2. Interestingly, mutation of T24 caused 
significant loss in activity at rα1β1δε, but gain in activity on rα3β2. Thus,  in 
comparison with the examined residues (12 residues) of Oh9-1, that are 
highly-sensitive, sensitive, less-sensitive and insensitive to mutations, we have 
delineated the functionally important residues of Oh9-1 to bind to α1β1εδ and 
rat α3β2 nAChR subtypes (summarised in table 3.2 and denoted in Figure 3.3), 
although loop-II residues of Oh9-1 were more critical for interactions and 
form the common binding core (M25, F27), specific residues encompassing 
loops –I, -II and -III appear to distinguish between these two receptor 
subtypes. Overall, our results show that, like with α-neurotoxins, loop-II 
residues are critical for receptor interactions, but that distinct Oh9-1 residues 





Table 3.2 Effect of alanine mutations in Oh9-1 on 
a
inhibition of nAChRs  
 
a
Extent of loss and gain in the inhibition, due to mutations are denoted by asterisks 
(depicting in statistical values; ***p < 0.001, **p < 0.01, *p < 0.05) and colour coded to 
map the critically important residues distinguishing between the two α1β1εδ and rat 
α3β2 nAChR subtypes. Red asterisks indicate the statistical significance for the gain in 




Figure 3.3 Functional determinants of Oh9-1, delineated on the basis of 
mutational analysis of single alanine mutations at 12 positions. A) 
Illustration of significance of alanine mutations in the activity of Oh9 -1(predicted 
structure) on α1β1εδ subtype. B) Illustration of significance of alanine mutations in the 
activity of Oh9-1 (predicted structure) on rat α3β2 subtype. Residues mutated are 
highlighted in stick and sphere model. Respective 180° rotation views are also shown to 
highlight the side chains of the residues extending in both faces of the predicted 
structure. They are colour coded on the basis of their order of significance in the loss or 
gain in the activity as denoted in table 3.1. The loops are labelled.  
 
The binding surfaces of Oh9-1 and α-neurotoxins are different – The 
residues in ETx and α-CBTx (short- and long- α-neurotoxins) that bind to 
Torpedo marmorata nAChR were determined by site-directed mutagenesis 
(Antil-Delbeke et al., 2000; Antil et al., 1999; Tremeau et al., 1995). Common 
core residues were identified that are located in comparable positions of their 
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three-dimensional structures and that are conserved in most short-chain, long-
chain and non-conventional, Candoxin, (Nirthanan et al., 2002) α-neurotoxins. 
Substitution of these residues causes significant loss in binding affinity (Antil-
Delbeke et al., 2000; Pillet et al., 1993). Other than these common core 






 at the tip of loop-I. 
However, probably due to its shorter length, loop-I of α-CBTx is not involved 
in receptor interaction. Instead, Phe
65
 in the C-terminal plays a role (Antil-
Delbeke et al., 2000; Bourne et al., 2005; Fruchart-Gaillard et al., 2002). In 
contrast to α-neurotoxins that interact only via the concave side of loop-II 
(Bourne et al., 2005; Teixeira-Clerc et al., 2002), Oh9-1 interacts with rα1β1εδ 
nAChR via both sides of the β-strand (Thr23-Thr24-Met25-Phe26-Phe27). In α-
neurotoxins, mutation at the tip of loop-II (Arg
33
 to Glu) causes 318- and 720-





 at the tip of Oh9-1 loop-II did not impact on interaction 
with nAChRs. In contrast to α-neurotoxins and despite their being shorter, 
Oh9-1 interacts with rα1β1εδ nAChR via loops-I and –III (His7, Lys45 and 
Tyr
46
). Therefore, Oh9-1 has a distinct functional site that facilitates its 
interaction with the ACh-binding pocket of nAChRs. 
Distinct but overlapping functional sites in Oh9-1 interact with different 
nAChR subtypes – Only long-chain α‐neurotoxins bind to both the muscle‐
type α1β1εδ and neuronal α7 nAChRs. Mutagenesis analysis of α-CBTx has 
identified 10 residues as important for binding to α7 receptor (Fruchart-
Gaillard et al., 2002). In the structure of the α-CBTx–AChBP complex, these 
residues are positioned within contact distance of AChBP residues (Bourne et 
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al., 2005). The residues at the tip of loop-III (beyond residue 65) do not 
contribute to receptor interactions, which is consistent with the structure–
activity studies showing that the loop-III residues and C-terminal 67–71 
stretch contribute weakly to binding (Fruchart-Gaillard et al., 2002). Although 
mutation of loop-I residues of α-CBTx did not affect  α-CBTx binding to 
Torpedo muscle (Antil et al., 1999) and α7 nAChR (Antil-Delbeke et al., 
2000), X-ray structural analysis of the α-CBTx–AChBP complex revealed that 
the tip of α-CBTx loop I, residues Ile5–Asp8 are closer to the tip of loop C of 







 affect α-CBTx’s binding to both receptors. However, residues 













), and the combination of a long 
loop-II and short loop-I in long-chain α-neurotoxins, may confer specificity 
for the α7 receptor (Bourne et al., 2005; Fruchart-Gaillard et al., 2002). Thus, 
α-CBTx interacts with Torpedo marmorata nAChR with its concave side but 
binds to neuronal α7 receptor with both sides. Oh9-1 also interacts with both 
muscle‐type (rα1β1εδ) and neuronal (rα3β2) nAChRs.  Interestingly, Oh9-1 







), whereas both sides of loop-II are involved in 
interaction with rα1β1εδ nAChR. Thus, surface binding and interactions of 
Oh9-1 with nAChRs are distinct from those of a-neurotoxins.    
Ω-neurotoxins are a novel class of 3FTxs – Our pharmacological studies 
revealed that Oh9-1 binds at the ACh-binding site on nAChRs, despite the lack 
of canonical α-neurotoxin functional residues. We identified 10 key residues 
 117 
 
in Oh9-1 that form a distinct functional site. Eight 3FTxs from Ophiophagus 
hannah venom showed high sequence similarity to Oh9-1 (Figure 1A). 
Interestingly, all 10 residues that were identified as important for interaction of 
Oh9-1 with nAChRs are either unchanged or replaced by conserved residues 
in these eight Oh9-1 isoforms.  These residues are conserved in SNTX11, 
Oh5, SNTX14, SNTX26 and Oh46, but SNTX6 has one (F27S), Oh32 two 
(F26P and Y46N) and Oh26 three (K22Q, F26P and Y46N) substitutions. 
Therefore, although their subtype selectivities and affinities could differ, these 
toxins may bind to nAChRs. In contrast, CM-1b and mambalgin have six and 
seven of the 10 functional residues substituted, respectively. Further, Oh9-1 
and other closely related isoforms are organized as a robust monophyletic 
group of nAChR antagonists containing the alternate functional site (Figure 7). 
The group is divergent from short- (type I) and long-chain (type II) a-
neurotoxins from Naja species, Australian elapid snakes and mambas, and 
from non-conventional (Kini and Doley, 2010)  or orphan group II Naja 
species toxins (Fry et al., 2003a).  To signify this distinction from a-
neurotoxins’, we suggest naming the class of 3FTxs containing Oh9-1 and 
closely related isoforms ‘Ω-neurotoxins’.  
3.5 Conclusions 
In conclusion, we have delineated the functional determinants of Oh9-1 to 
interact with α1β1εδ and α3β2 subtypes by alanine scanning mutational 
analysis. These findings in combination with detailed structural analysis may 
contribute in defining the specific residues of Oh9-1 that are liable for its 
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Meanwhile, we came across another novel three-finger toxin, exactin, 
which was being characterized in our lab. Exactin was isolated from 
Hemachatus haemachatus venom and it also has 57 amino acid residues. It 
was shown to inhibit blood coagulation by inhibiting FX activation by extrinsic 
tenase complex and hence the name Extrinsic activation inhibitor/Exactin (VM 
Girish, PhD thesis, National University of Singapore, 2012). Amino acid 
sequencing of exactin and its comparison with homologous sequences revealed 
that, exactin exhibited sequence identity (>58%) to many short-neurotoxins from 
O. hannah. Most of them were not functionally characterized (He et al., 2004; Li 
et al., 2006) except for the toxin Oh9-1 (Chang et al., 2002). Evaluation of 
neurotoxic effects of exactin in (in vivo toxicity studies) mice, showed neurotoxic 
symptoms, indicating its biological role in affecting the neurotransmission. In 
ex vivo experiments, on neuromuscular junction using CBCM preparations, 
exactin exhibited a reversible postsynaptic blockade of neuromuscular 
junction with an EC50 value of 4.4 μM (VM Girish, PhD thesis, National 
University of Singapore, 2012).  
During detailed examination of the primary structures of exactin in 
comparison with Oh9-1, we recognised that exactin shares an identical loop-II 
with Oh9-1 (Figure 4.1) and due to this, exactin also lacks all the previously 
mentioned critically important residues of α-neurotoxins to bind to nAChRs 









Figure 4.1 Comparison between the amino acid sequences and predicted structures of Oh9-1 and exactin (A) Sequence alignment of Oh9-1 
with exactin. Toxin names, species, and (ACCN) accession numbers are shown. Disulphide bridges and loop regions are also show n. At the end of each sequence, 
the number of amino acid residues is stated. The homology (sequence identity) of exactin is compared with Oh9-1and shown at the end of the sequence. Conserved 
amino acids residues other than the cysteines are highlighted in the yellow. (B) Illustration of identical loop-II (highlighted in green) and variant loops –I and –III 
(highlighted in blue) in the predicted structures of exactin in comparison with that of Oh9 -1
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Exactin also shared similar structural properties of Oh9-1 in terms of the 
differences in the lengths of loop-I (5 residue shorter), loop-II (a residue 
longer) and loop-III (3 residue shorter), in comparison with erabutoxin-b 
(Figure 4.1). Attributable to these primary structural similarities, exactin was 
more comparable to Ω-neurotoxin (Oh9-1) than α-neurotoxin (erabutoxin-b).  
Therefore, we were keen on elucidating the subtype selectivity of exactin, a 
paralogue of Oh9-1 to understand the importance of identical loop-II tip-
region (-T-T-M-F-F-P-N-H-P-V-) in combination with completely different 
loops –I and –III.   
 
4.2 Materials and Methods 
4.2.1 Materials 
All the materials used are described in chapter two, section 2.2.1 
4.2.2 Methods 
Electrophysiological studies of exactin to determine subtype-selectivity 
Electrophysiology experiments of exactin on various two-electrode voltage 
clamped nAChR subtypes, expressed in Xenopus oocytes were conducted as 




In order to obtain a subtype selectivity profile, exactin at 
§§
100 μM 
concentration was screened for its effect on currents evoked by EC50 
concentrations of ACh for each nAChR subtype expressed on Xenopus oocyte. 
Various nAChR subtypes namely rat muscle type [both adult (α1β1εδ) and 
fetal (α1β1γδ)], human neuronal α7, α9α10, α4β2, α4β4, α3β2 and α3β4 
subtypes, were screened (Figure 4.8A). At 100 μM concentrations, exactin 
showed more than 90% to 100% inhibition on α1β1εδ α1β1γδ α7 and α9α10 
subtypes, whereas on α4β2 exactin showed  55% to 60% inhibition. In 
contrast, the inhibition exhibited by exactin on α3β2, α3β4 and α4β4 subtypes 
was around to 20% to 30% only. Thus, exactin was more selective towards 
[both adult (α1β1εδ) and fetal (α1β1γδ)] muscle type like Oh9-1. In addition, 
exactin was also selective towards human neuronal α7, α9α10 subtypes unlike 
Oh9-1 (Figure 4.7 A), indicating that exactin subtype selectivity profile, which 
is different from Oh9-1.  
Further, the binding parameters of exactin were determined on muscle type 
α1β1εδ and human neuronal α7 and α9α10 receptor. These subtypes are the 
main targets of exactin in term of affinity. Exactin (0.3-30μM; n = 3) could 
inhibit the currents evoked by ACh in a dose-dependent manner for the above 
mentioned subtypes (Figure 4.2 B). The IC50 of exactin for α1β1εδ, α7 and 
α9α10 nAChR subtypes was further determined to be 4.6 ± 1.2 µM, 8 ± 0.9 
µM and 10.6 ± 1.2 µM, respectively, indicating that exactin antagonizes these 
nAChR subtypes at micro-molar concentrations (Figure 2.7 C). Hill’s 
                                                 
§§
 Exactin showed more than 90% inhibition at 30 μM concentration on rat muscle type αβδε 
receptor subtype. Therefore, Exactin was not tested at higher concentration on αβδε receptor. 
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coefficient of exactin binding to α1β1εδ, α7 and α9α10 were determined to be 
-3.2, -3.7, -2.5, respectively, suggesting that exactin binding mediates positive 
cooperativity in ligand-receptor interaction (Langley, 1905; Prinz, 2010; Prinz 
and Maelicke, 1983) (Edelstein and Le Novère, 2013). This positive 
cooperativity could be explained in reference to the presence of multiple 
binding sites in these subtypes. 
This result indicated that each molecule of exactin bound to the receptor 
increases the affinity for the second molecule to bind. It should be noted that 
there are two non-identical ligand-binding sites on both α1β1εδ nAChR i.e., at 
interfaces; α (+)/(-)δ, α(+)/(-)ε, whereas in α7 there are five identical ligand-
binding sites i.e., at interfaces; α7(+)/(-)α7 and Oh9-1 binds to different ligand 
–binding sites within a receptor subtype, with similar affinities and the (+) face 
of the α9 subunit has been considered the principal binding site for α9;α10 
nAChRs (Perez et al. 2009) and exactin binds to different ligand –binding sites 
within a receptor subtype, with cooperative affinities. 
Exactin shares an identical tip-region of loop-II with Oh9-1, 
nevertheless exactin shows a distinct subtype selectivity profile than Oh9-
1. Due to the presence of same loop-II tip-region as Oh9-1, exactin also 
lacks all the previously described critically important residues for 3FTxs 
to interact with nAChRs. Despite this replacement, exactin still showed 





Figure 4.2 Inhibition of nAChR subtypes expressed in Xenopus oocytes by 
exactin.  (A) Bar graph illustrating the nAChR subtype selectivity of exactin in 
comparison with Oh9-1. (C) Concentration-response curves of Oh9-1 on selective 
nAChR subtypes which gave IC50’s of 4.6 ± 1.2 µM, 8 ± 0.9 µM and 10.6 ± 1.2 µM for 
rat α1β1εδ (adult), human α7 and α9α10 receptors respectively. Data represents mean ± 








  Exactin was characterized as a novel three-finger toxin with a dual function; 
(i) a potent and specific anticoagulant effect on the FX activation by the 
complete extrinsic tenase complex  and (i) a weak, and reversible, postsynaptic 
neurotoxicity effect on Chick neuro-muscular junction (VM Girish, PhD 
thesis, National University of Singapore, 2012). Sequence analysis of exactin 
showed that it shares identical loop-II with Oh9-1 (Figure 4.1) and due to this, 
exactin also lacks all the previously mentioned critically important residues of 
α-neurotoxins to bind to nAChRs (Pillet, Menez et al., 1993) (Antil et al., 
1999) (Nirthanan Matthew C.E. Gwee., 2004). Exactin also shared similar 
structural properties of Oh9-1 with 57 amino acid residues and also in terms of 
the lengths of loop-I, -II and -III. Therefore, exactin was more comparable to 
Ω-neurotoxin (Oh9-1), more specifically a paralogue of Oh9-1 than α-
neurotoxin (erabutoxin-b).  
We hypothesized that the subtype selectivity profile of exactin could help to 
understand the impact of different loop-I and loop-III on the loop-II, which is 
identical to the tip-region of Oh9-1 loop-II.  The alanine-scan mutational 
analysis of Oh9-1 had revealed that the residues of loops -I and -III influence 
its subtype selectivity. Therefore, we expected that the presence of completely 
different residues in loops -I and –III of exactin will bring about a different 
subtype selectivity profile than Oh9-1.   
As expected, exactin exhibited selectivity towards [both adult (α1β1εδ) and 
fetal (α1β1γδ)] muscle type like Oh9-1. In contrast, exactin was also selective 
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towards human neuronal α7, α9α10 subtypes unlike Oh9-1 (Figure 4.7 A). 
This suggested that loop-I and loop-III are involved in nAChR subtype 
selectivity.  
Vis-e-vis exactin anti-coagulant effect [IC50 of 4.05 ± 0.32 μM] (VM Girish, 
PhD thesis, National University of Singapore, 2012), Oh9-1 was tested for its 
effect on the FX activation by the complete extrinsic tenase complex. Oh9-1 
had no effect, even at 10 μM concentration (data not shown). This indicates 
the probable role of loops –I and –III of exactin in its anti-coagulant effect. 
This has to be evaluated by site-directed mutagenesis of exactin. 
Furthermore, the binding parameters of exactin on muscle type α1β1εδ and 
human neuronal α7 and α9α10 receptor, determined by the concentration 
response curves, indicated that exactin antagonizes these nAChR subtypes at 
micro-molar concentrations (Figure 2.7 C). In comparison to Oh9-1 (hill’s 
coefficient < -2), the hill’s coefficient of exactin were more than -2 (-3.2, -3.7 
and -2.5 for α1β1εδ, α7 and α9α10, respectively) suggesting a probable 
influence of loop-I and loop-III of exactin in mediating positive cooperativity 
in ligand-receptor interaction (Langley, 1905; Prinz, 2010; Prinz and 
Maelicke, 1983) (Edelstein and Le Novère, 2013).  
These findings provide insights for identifying specific residues that can 
influence subtype selectivity and also confer positive cooperativity to 3FTxs. 
This information can be exploited to design specific nAChR antagonists which 
can be of high importance as research tools as well as a therapeutic leads. In 
this particular context, designing the α9α10 specific antagonist with higher 
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affinity is of imperative interest. Because recent studies have showed that 
α9α10 antagonists are analgesic in neuropathic pain models (Vincler et al. 
2006; McIntosh et al. 2009) and α9α10 nAChR has also been implicated in 
wound healing, human breast and lung cancer (Lee et al. 2010; Chikova and 
Grando 2011; Lee et al. 2011; Wu et al. 2011; Chikova et al. 2012). Thus, 
there is an urgent need for understanding the molecular pharmacology of the 
human α9α10 receptor, which demands specific ligands.  
4.5 Conclusions 
In conclusion, we have evaluated the subtype selectivity of exactin, another 
Ω-neurotoxin. Despite an identical loop-II as in Oh9-1, exactin has a different 
nAChR subtype selectivity profile and exhibits positive cooperative binding to 
nAChR subtypes. Thus, indicating the role of loop-I and loop-III of exactin in 

















In previous chapters we described the structural and functional 
characterisation of two unique 3FTxs. On this basis, we explained that they 
belong to a new class of 3FTx family called Ω-neurotoxins. Following these 
structural and functional characterisation studies phylogenetic analyses of 
these 3FTx have been performed to investigate the relevance of their new 
classification Ω-neurotoxins. Thus, molecular phylogeny was used in order to 
establish phylogenetic relationships between these toxins intrinsically, and 
between these toxins and other functional groups of 3FTx. 
5.2 Materials and methods 
Molecular phylogeny 
a) Sequences alignment  
Representative three-finger toxins of each well-characterized group of three 
finger toxins (like neurotoxins, cytotoxins and weak toxins) were retrieved 
from the UniProt Knowledgebase. Toxins are indicated by their Swissprot 
accession number, their common names and by the names of the snake 
species. Toxins were aligned by MUSCLE implanted in MEGA6 (Tamura et 
al., 2011). Alignment was visualized and inspected manually for eventual 
errors with the alignment visualizer supplied by MEGA6.  
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b) Phylogenetic reconstruction 
Phylogenetic trees were reconstructed using the maximum likelihood 
method (Felsenstein, 1981). MEGA6 was used to choose the best-fit 
substitution model, and for tree reconstruction, visualization and annotation. 
Bootstraps support values based on 200 replicates. 
5.3 Results  
The toxins selected in this study are Oh9-1 and its 7 isoforms from 
Ohphiophagus hannah venom (SNTX6, SNTX14, SNTX26, OH46, OH5, 
OH26, OH32) and exactin from Hemachatus haemachatus were aligned with 
representative three-finger fold toxins belonging to the curaremimetic type-I, 
type-II and type-III α-neurotoxins, kappa-neurotoxins, cytotoxins and 
aminergic toxin (Blanchet et al., 2014)  groups (Figure 5.1). Our results show 
that Ω-neurotoxins are organized as a robust monophyletic group with nAChR 
antagonising function through novel functional site (Fig. 4). This group is 
divergent from type I and type II a-neurotoxins (from Naja sp, australians 
elapidae snake and mambas), from orphan group II toxins (Naja sp) and finally 
from 3FTx found in “colubrids” which serve as external group. This 
reconstruction highlights a functional organization of the 3FTx reinforcing the 







Figure 5.1 Maximum likelihood tree of ω-neurotoxins and functional 
elapid 3FTs. Sequences from Boiga dendrophila, Thrasops jacksonii and Dispholydus 
typus have been used as outgroups. The best evolutionary model found by MEGA6 was 
the WAG model using a discrete Gamma distribution (+G) and with invariance on 
certain site (+I). The tree was manually edited with the tree viewer tool supplied by 
MEGA6. The functional groups were annotated based on Fry’s nomenc lature (Fry et al., 
2003b) or on common named accepted in the literature. Bootstrap values were based on 
200 replicates. Values below 50% are omitted. 0.05 = Mean of substitution per site. 




Unusual functional convergence in Ω-neurotoxins – Protein domains are 
evolutionary units that play important roles in diversity of structure and 
function. As described above, 3FTxs are an example of functional and 
evolutionary divergence. In contrast, non-homologous proteins are structurally 
distinct but can exhibit similar function through convergent evolution. Several 
distinct protein scaffolds have evolved as nAChR antagonists (Tsetlin, 2015). 
In addition to 3FTx, phospholipase A2 (PLA2), waglerin and azemiopsin 
scaffolds in snake venoms target nAChRs. Among the nAChR antagonists, 
those using 3FTx scaffolds are most common and are abundant with a wide 
range of isoforms in elapid and hydrophiid snake venoms. In addition, human 
Ly6 proteins (Lynx-1, PATE4, SLURP1 and SLURP2) interact with nAChRs 
(reviewed in (Tsetlin, 2015)). A small number of PLA2s exhibit postsynaptic 
activity and they interact with nAChRs (Bon and Saliou, 1983; Petrova et al., 
2012; Vulfius et al., 2011). So far, only two waglerins (Wtx-1 and Wtx-2) 
from Tropidolaemus (formerly Trimeresurus) wagleri venom (Weinstein et 
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al., 1991) have been purified and characterised. They have 22-24 amino acid 
residues and one disulphide bond. Azemiopsin, from Azemiops feae viper 
venom, is the first natural toxin that blocks nAChRs and does not have 
disulphide bridges (Utkin et al., 2012). Interestingly, the C-terminal segments 
of waglerins and azemiopsin exhibit significant similarities (Utkin et al., 
2012). In Conus venoms, nAChR antagonists have evolved with a-conotoxin 
(monomeric) and αD-conotoxin (dimeric) scaffolds (Lebbe et al., 2014; 
Loughnan et al., 2009). Despite the structural diversity (Figure 8), all these 
proteins bind the ACh-binding pocket of nAChRs. Varied folding of these 
protein scaffolds mandate distinct functional site residues for the molecular 
recognition of the same site in nAChRs (Kini and Doley, 2010; Lebbe et al., 
2014; Vulfius et al., 2014). Thus, differing but convergent evolutionary 
pathways have led to targeting of the ACh-binding pocket, the critical, 
susceptible site in this group of receptors. Ω-neurotoxins represent yet another 
convergent evolutionary path. They share a similar three-finger fold structure 
with a-neurotoxins, but bind to the Ach binding pocket of nAChRs via 
different functional residues. Thus, Ω-neurotoxins represent an unusual and 





Figure 5.2 Convergent evolution of toxins that target nAChRs.  (A) Structures of 
nAChR antagonists. Shown are structures of a long-chain α-neurotoxin (1L4W), α-
conotoxin (1AKG) and a post-synaptic PLA2 (vurtoxin, molecular model built by 
homology to ammodytoxin (PDB 3G8G)). Structures of Waglerin, Azemiopsin and αD-
conotoxins were not found in the database. Proteins with different structural folds have 
evolved to target the ACh-binding site in nAChRs. (B) Interaction of antagonists with 
the ACh-binding pocket interface of the nAChR subunit. Structures of α -bungarotoxin 
binding with the α9 monomer extracellular domain (4UY2), and α-conotoxin binding 
with the AChBP monomer (2BR8), and a model of the vurtoxin complex with the 
receptor at the α-γ subunit interface of the Torpedo californica nAChR (Vulfius et al., 
2014) are shown. Loop C, the characteristic feature of the principal face of ACh-binding 
pocket is labelled.  
In addition, the proximity of type-III α-neurotoxins in this phylogenetic tree 
supports a potential nAChR antagonism (at micro-molar range) (Barnett, 
1979) function of this group of toxins, but with different functional 





Figure 5.3 Comparison of three-dimensional structural models of α- and 
Ω- neurotoxins. (A) Erabutoxin (ETx), type-I short-chain α-neurotoxin (PDB code 
5EBX). (B) α-Cobratoxin (α-CBTx) and type-II long-chain α-neurotoxin (PDB code 
2CTX).  (C) Oh9-1, Ω-neurotoxin (as predicted by i-TASSER software). Conserved 
common binding core residues and specific functional residues of type-I and type-II and 
are shown in stick model mode and highlighted in red. Novel functional site of Oh9 -1, 
Ω-neurotoxin is shown in blue stick model mode. Disulphide bridges are highlighted 
only in type-II α-neurotoxin. Loops of the 3FTxs are labelled. Note: (i) The functionally 
critical residues in α-neurotoxins are on the concave side of the molecule, whereas in 
Oh9-1, the functionally important residues are on both sides of the molecule. (ii) Type -I 
α-neurotoxin has a longer loop-I and shorter loop-III; Type-II α-neurotoxin has shorter 




In this context, we explain the structure-activity studies and the phylogenic 
analysis of Ω-neurotoxins as a “special case” of functional convergence to 
antagonise nAChRs, but with a profoundly novel functional site while 



















This thesis reports the characterisation of a novel three-finger toxin, Oh9-1, 
from king cobra venom and the nAChR subtype interaction of exactin, a 
paralogue of Oh9-1. Structural and functional characterisation of Oh9-1 and 
exactin has revealed that they are significantly distinct from the α- and κ- 
neurotoxins. Therefore it belongs to a new class Ω-nuerotoxins, of 3FTx 
fmaily.  
Sequence alignment of  Oh9-1 with the well characterized canonical short-
chain α-neurotoxin, erabutoxin-b (Eb-b), showed that Oh9-1 has a much 
shorter loop-I (5 residue shorter) and loop-III (3 residue shorter), whereas a 
residue longer loop-II in comparison with Be-B (Figure 2.0). In addition, Oh9-




































/_(erabutoxin a/α-cobratoxin numbering), that are reported to be crucial 
for the α-neurotoxins to bind and antagonize nAChRs with high affinity 
(Pillet, Menez et al., 1993) (Antil et al., 1999).  
Although they belong to 3FTx family, the conserved functional residues of 
α-neurotoxins are completely replaced in this group. For detailed structural 
and functional analysis Oh9-1 was recombinantly expressed, refolded and 
purified to homogeneity. In addition, the monomeric nature of Oh9-1 was 
confirmed by analytic gel filtration profile, where Oh9-1 elutes at the retention 
volume as aprotinin (6.5 kDa). The activity of the recombinant Oh9-1 was 
tested on chick neuromuscular junction. Despite structural differences and the 
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absence of previously described key functional determinants, refolded Oh9-1 
was found to be postsynaptic reversible neurotoxin on ex-vivo neuromuscular 
junction with an IC50 of 31 ± 2.7 μM. The neuromuscular blockade effect was 
further confirmed by electrophysiology studies on expressed subtypes 
nAChRs. Therefore, it was interesting for us to know whether Oh9-1 with a 
new functional site,  interacts with nAChRs on the same site as α-neurotoxins 
or on different site.  
Interestingly, Oh9-1 showed competitive antagonism towards ACh binding 
pocket of nAChRs. This suggests that Oh9-1 binds at ACh binding site of 
nAChR as α-neurotoxins, but with profoundly novel molecular recognition 
determinants, which has not been described so far in three-finger neurotoxins. 
Therefore, Oh9-1, belongs to a novel class of 3FTx family, called Ω-
neurotoxins.  
Additionally, I investigated the nAChR subtype selectivity profile of Oh9-1 
to understand the pharmacology of its novel functional site. In 
electrophysiological studies, Oh9-1 showed subtype selectivity towards rat 
muscle-type α1β1εδ/α1β1γδ (adult/fetal) and rat neuronal α3β2 subtypes 
among the tested 10 different nAChR subtypes from human and rat. The  
IC50’s of Oh9-1 are  3.1 ± 1.1 µM, 5.6 ± 1.1  µM and 50.2 ± 1.1 µM, for rat 
muscle-type α1β1εδ/α1β1γδ (adult/fetal) and rat neuronal α3β2 subtypes, 
respectively. This showed that activity of Oh9-1 is in micro-molar range when 
compared to nano-molar active α-neurotoxins.  In addition, the binding 
parameters of Oh9-1 were deduced from the hill’s coefficient of the 
concentration response curves of Oh9-1 (Edelstein and Le Novère, 2013). This 
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suggested that Oh9-1 binding is non-cooperative in ligand-receptor interaction 
which means that each molecule of Oh9-1 bound to the receptor does not 
affect the affinity for the second molecule to bind. The novel and interesting 
findings of this characterisation further led us to delineate the functional site as 
well as elucidate the structure-function relationship of Oh9-1.  
Structure-function relationship studies of Oh9-1 were carried out to 
investigate these novel structural and functional determinants. In order to co-
crystallize the protein with the acetylcholine binding protein (AChBP), the 
homolog for the ligand binding domain of nicotinic receptors, I analysed the 
interaction of Oh9-1 with AChBP using competitive radioligand binding 
experiments. Oh9-1 did not compete with the radioligand to interact with 
AChBP. Simultaneous attempts to solve the 3D structure of free Oh9-1 by X-
ray crystallography methods are currently in progress.  
I came up with 12 alanine scanning mutants encompassing the tips of all the 
three loops of Oh9-1 by site-directed mutagenesis studies to define the 
structure-activity relationships of Oh9-1. In comparison with the examined 
residues (12 residues) of Oh9-1, that are highly-sensitive, sensitive, less-
sensitive and insensitive to mutations, I have delineated the functionally 
important residues of Oh9-1 to bind to α1β1εδ and rat α3β2 nAChR subtypes. 
Although loop-II residues of Oh9-1 were critical for interactions, specific 




Furthermore, I also evaluated the subtype specificity of Exactin, a 
paralogue of Oh9-1, from Hemachatus haemachatus venom, a reversible, 
postsynaptic neurotoxin (VM Girish, PhD thesis, National University of 
Singapore, 2012). Despite sharing identical loop-II with Oh9-1, Exactin 
exhibited distinct subtype selectivity; it binds to rat α1β1εδ, human α7 and 
α9α10 subtypes, indicating the importance of loops-I and -III residues in 
subtype selectivity and exhibits positive cooperative binding to nAChR 
subtypes. Thus, indicating the role of loop-I and loop-III of exactin in subtypes 
selectivity and binding parameters of exactin. 
Phylogenetic analyses of these 3FTxs were performed which revealed a 
functional organization of the 3FTx reinforcing the concept of Ω-neurotoxins 
in an evolutionary point of view. In this context, we have explained the 
structure-activity studies and the phylogenic analysis of Ω-neurotoxins as a 
“special case” of functional convergence to antagonise nAChRs, but with a 
profoundly novel functional site while retaining the compact three-finger fold. 
To summarize, I have characterized functionally and structurally unique 
three-finger neurotoxin Oh9-1, the member of new class, Ω-neurotoxins. I 
have evaluted the mode of interaction of Oh9-1 and delineated its functional 
determinants by alanine-scan mutational studies. I have also evluated the 
subtype-selectivity of exactin, a paralogue of Oh9-1. With the obtained results, 
I describe the importance of loops –I and –III  of  Ω-nuerotoxins in subtype-
selectivity and co-operative binding parameters. Thus, establishing the 
occurrence of  a novel class of 3FTxs by point of view of both structure-
funtion relationships and by evolution (through phylogenetic analysis). 
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Therefore, the findings of this study may be explained as a “special case” of 
functional convergence snake venom three-finger neurotoxins through the 
novel class ‘Ω-neurotoxins’.  
6.2 Future prospectives 
The work described in this thesis has addressed; 
a) The pharmacological characterization and  structure-activity 
relationship of Oh9-1 through alanine scanning mutational studies 
b) nAChR subtype-selectivity of  exactin 
However, there still remains some imperative questions in this research,  
answers for which will open up new avenues of investigation in the future. 
Some of the future prospectives are discussed below. 
6.2.1 Determination of 3D structure of Oh9-1 and Exactin: 
It would be interesting to solve the 3D structure of these unique toxins, in 
order to understand the similarity or difference in their mode or mechanism of 
interaction (which lacks most of the critically important residues and shares an 
identical loop-II) with nAChR. 
 If protein crystals are not obtained then nuclear magnetic resonance 
(NMR) can be used to determine its structure. For three dimensional structure 
determination by NMR, 15N- and 13C-labeled protein needs to be expressed 
and purified. Before doing 3D NMR experiments, heteronuclear single 
quantum correlation (HSQC) (2D NMR) of the protein sample should be taken 
to check the peak dispersion. The labour-intensive process of structure 
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determination is undertaken when peaks in HSQC are well-dispersed and 
number of peaks are almost equal to the number of amino acid residues 
excluding the proline residues in the protein. 
6.2.2 Further pharmacological characterisation of Oh9-1: 
In this thesis, we report the structure-activity relationship of Oh9-1 with 
first generation mutations. We also report that Oh9-1 binds to same pocket in 
nAChR as α-neurotoxins with different functional determinants than α-
neurotoxins. In relation to this observation, it would very interesting to 
delineate the interacting partners of  Ω-neurotoxins on ACh-binding pocket of 
nAChR. This can be achieved by further structure-activity relationships of 
Oh9-1 by second generation mutational analysis of Oh9-1 and double-cycle 
mutational analysis on ACh-binding pocket in the receptor (as our attempts to 
co-crystallise Oh9-1 with AChBP were unsuccessful).  
In this regard, I had a chance to screen wild-type Oh9-1 on six mutants of 
rat α3β2 subtype, available at Professor David J Adams lab. The mutations 
were purely on the basis of sequence differences at loop-C between the rat 
α3β2 and human α3β2. The subunit mutations (Three α3-subunit mutants and 
three β2-subunit mutants) generated were expressed with rat receptor subtype 
backbone, where the residues of rat receptor subunits were mutated to 
respective human receptor subunits; rat α3[Q198P]β2,  α3[Q73G,V75A]β2, rat 
α3[D97V]β2, α3β2[D73E], α3β2[I181V] and α3β2[D165E]. Oh9-1 lost 
activity significantly towards the receptor mutant rat α3[Q198P]β2 and rat 
α3[D97V]β2 than other receptor mutants, indicating that the importance of 
Q198 and D97 for effective interaction of Oh9-1 with rat α3β2 than human 
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α3β2 subtype (Figure 6.1).  This revealed that specificity of Oh9-1 exhibited 
towards rat α3β2 than human α3β2, is steered by α3 subunit contributing to the 
principal face of ACh-binding site than the non-principal face of β2 subunit. 
 
Figure 6.1 Screening of Oh9-1 on the mutant rat α3β2 subtypes. Bar graph 
illustrating the activity of Oh9-1 on; rat α3[Q198P]β2, α3[Q73G,V75A]β2, rat 
α3[D97V]β2, α3β2[D73E], α3β2[I181V] and α3β2[D165E subtypes. Data represents 
mean ± SEM, n= 3.  
However, further studies need to be conducted to delineate the interacting 
partners of Oh9-1 on ACh-binding pocket of the nAChR subtypes. 
6.2.3 Elucidating the structure-activity relationship of exactin 
Here, we report the nAChR subtype-selectivity of  exactin and provide 
evidence for the involvement of loop–I and loop–III in the subtype-selectivity 
and binding parameters of  Ω-neurotoxins. Therefore, delineation of functional 
determinants that are critical for these charcteristics of  Ω-neurotoxins, would 
be interesting. This can be achieved by site-directed mutational analysis of 
exactin, This would also help us understand the structure-activity relationship 
of exactin’s dual function. 
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These studies may provide a fundamental basis for the design of highly 
selective ligands for nAChR subtypes. In the long run, these findings may 
facilitate in designing a chimera of α-neurotoxin (with high nAChR affinity) 
and Ω-neurotoxin (with determinants conferring subtype selectivity). Such a 
ligand chimera would address many questions associated with the normal 
physiology of nAChR subtypes and also could be used as therapeutic lead for 















Figure A.1 Vector map and the MCS of pET-22b. (A) Vector diagram of pET-
32a with all the essential features of the vector. (B) The region corresponding to the 











Table A.3 RP-HPLC chromatograms  of  the prification of  refolded, 12 Oh9-1 alanine mutants and their ESI mass spectrum. They are 
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